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Abstract 
The post-synaptic side of an excitatory synapse is characterized by an electron-dense, 
highly dynamic architecture of proteins, called the post-synaptic density or PSD. 
PSDs comprises of a diverse group of proteins, from glutamate receptors, scaffolding 
proteins, signaling molecules and cyto-skeletal elements. Amongst this protein en-
semble, the MAGUK family of scaffolding proteins is well known for their roles in 
synaptic maturation, glutamatergic receptor organization and for serving as platform 
for post-translational modifications of other proteins in the PSD. PSD-93, one of the 
lesser-known members of this family of proteins had been reported to have contradic-
tory functions in maintaining AMPA and NMDA receptor levels in different brain 
regions. In this study, using diverse biochemical approaches in a mouse model, I stud-
ied the role of PSD-93 in maintaining surface level of glutamatergic receptors and its 
patho-physiological significance in glutamate induced neuronal toxicity. 
By using surface protein cross-linking approach, I could demonstrate that in the layer 
2/3 visual cortex of a PSD-93 knockout mice, there is a reduction in the surface level 
of both NMDA receptor subunits GluN2A and GluN2B. Additionally, I could also 
demonstrate that this reduction in surface level of GluN2B is caused independent of 
the change in phosphorylation of the GluN2B-Y1472 site, possibly through other 
phosphorylation mechanism. 
Since, NMDA receptors are classically linked with glutamate-induced neurotoxicity 
during ischemic brain damage, I looked at the level of neurotoxicity in PSD-93KO 
cortical cultures. I established a NMDA challenge protocol that enabled neuronal 
apoptosis and I could show an almost 80% reduction in cortical cell death, when PSD-
93 is absent. This form of NMDA neurotoxicity was largely mediated via the GluN2B 
subunit of NMDA receptors and the neuro-protection effect in PSD-93KO was medi-
ated by perturbation of the P38 MAPK pathway of apoptosis induction.  
PSD-95 had been classically reported to link NMDA receptor activation with down-
stream apoptotic signaling cascade. I could show that deletion of both PSD-93 and 
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PSD-95 showed equal degrees of neuro-protection at lower doses of NMDA chal-
lenge whereas at higher doses, only PSD-93 retained its neuro-protective effects. 
Overall, my data helps to understand the role of PSD-93 in maintaining surface 
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1 Introduction 
Human brain comprises of over hundred billion neurons. More than hundred years 
ago (1886-1890) it was recognized by neuro-anatomist including His, Forel and 
Ramón Y Cajal, that nerve cells or neurons are independent units capable of self-
organized communications. Neural communication takes place between two neurons 
through highly specialized structures known as synapses. Each neuron, in human 
brain, on an average, have between 10,000-100,000 synapses, making the total num-
ber of synapses in a brain close to an astounding 1015. 
1.1 Synaptic Transmission 
Synapses are divided into electrical and chemical types. Electrical synapses are recip-
rocal pathways for ionic current flow, between adjacent neurons separated by only 2-3 
nm gaps (gap junctions). Due to their very rapid activity, electrical synapses are capa-
ble of mediating synchronization and spike activity among neuronal clusters. 
However, the majority of synapses in the brain are chemical synapses. They are more 
complex structures with a much higher capacity of having their synaptic transmission 
strength fine-tuned, based on their previous activity (synaptic plasticity). A chemical 
synapse has a pre-synaptic neuron separated from its post-synaptic counterpart by a 
gap of 20-30 nm, called the synaptic cleft. Transmissions at chemical synapses occurs 
when an action potential reaches the pre-synaptic terminal causing a change in the 
membrane potential and opening of the voltage-gated Ca2+-channels. A rapid and 
transient increase in the Ca2+ concentration in the presynaptic terminal causes neuro-
transmitter containing synaptic vesicles to fuse with the membrane and release their 
content in the synaptic cleft. The neuro-transmitter diffuses across the cleft to reach 
and bind to specific receptors on the post-synaptic membrane. This causes the post-
synaptic channels to open and allow the flow of ions in or out of the post-synaptic 
cell. This eventually alters the conductance and hence membrane potential of post-
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synaptic neurons causing them to fire an action potential. That is how information 
flows from one neuron to the next one. 
Depending on the type of neuro-transmitter released from the pre-synaptic terminal, 
neurons can be excitatory, inhibitory or modulatory in nature. In general, one neuron 
has one kind of neuro-transmitter: excitatory or inhibitory, while the modulatory neu-
ro-transmitters pair up with either of them. An excitatory synapse is one, where an 
action potential in the pre-synaptic neuron increases the probability of an action po-
tential in the post-synaptic neuron. The neuro-transmitter glutamate is involved in an 
excitatory synapse. An inhibitory synapse, on the other hand, helps causing change in 
the post-synaptic membrane in such a way, that it becomes more difficult for the neu-
ron to fire an action potential. GABA and glycine are the inhibitory neuro-
transmitters. 
1.2 Glutamatergic Excitatory Synapses 
Excitatory synapses in the brain are characterized by the neuro-transmitter glutamate, 
that can activate three classes of ionotropic receptors: AMPA, NMDA and kainate. 
All three classes of receptors are assembled as hetero tetrameric complexes. Addition-
ally, glutamate can also activate G-protein coupled metabotropic receptors, which do 
not conduct ions but triggers in intra-cellular signaling cascades. Excitatory synapses 
are formed on dendritic protrusions called spines. A spine head at an excitatory syn-
apse is typically characterized by a complex and highly dynamic architecture of pro-
teins called the post-synaptic density (PSD) (Sheng and Kim, 2011). The PSD is an 
electron-dense organization of proteins ranging from glutamate receptors, cell adhe-
sion molecules, cytoskeletal elements as well as downstream signaling enzymes. The 
general role of a PSD is to cluster the post-synaptic receptors efficiently opposite a 
pre-synaptic neuro-transmitter release site (active zone) and then couple the activation 
of the post-synaptic receptors with down-stream signaling cascades. 
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1.2.1 AMPA receptors 
AMPA receptors are known to exist as tetrameric assemblies of GluA1-GluA4. The 
different allele of this receptor differs mainly in their C-terminal part and bind differ-
ent interacting partners (Hollmann and Heinemann, 1994; Malinow and Malenka, 
2002). GluA2 is a key subunit in defining the properties of AMPA receptors. It gets 
post-translationally modified and renders the channel Ca2+-impermeable. AMPA re-
ceptors that lack the GluA2 subunits are susceptible to be blocked by polyamines at 
their C-terminal end and hence cannot pass current through them at positive mem-
brane potential. Thus for these receptors, when the current to voltage relationship is 
plotted experimentally, they are inwardly rectifying in nature (Hollmann and 
Heinemann, 1994; Hume et al., 1991; Jonas and Burnashev, 1995; Koh et al., 1995). 
The GluA4 subunit, whereas, determines the desensitization kinetics of the AMPA 
receptors (Mosbacher et al., 1994).Besides their roles in channel properties, the subu-
nit composition also influences the trafficking of these receptors as well (Bredt and 
Nicoll, 2003; Malinow and Malenka, 2002). 
When the abundance of the different subunit compositions were examined, it was 
found that cortical pyramidal neurons in the Layer 2-4 principally are Ca2+-
impermeable, i.e., contains GluA2 subunit and the expression pattern for both GluA2 
and GluR3 subunits in these cells were similar . Further it was found out that most 
cortical pyramidal cells contain the GluA1-GluA2 combinations and highly Ca2+-
impermeable (Kondo et al., 1997). In hippocampus, AMPA receptors are either di-
mers of GluA1-GluA2 (termed GluA1/2) or that of GluA2-GluR3 subunits (termed 
GluA2/3) (Wenthold et al., 1996). It is suggested that the GluA2/3 AMPA receptors 
are mainly responsible for basal synaptic transmission and are continuously recycled 
into the synapse on an average timescale of 15 min, whereas, the GluA1/2 AMPA 
receptors are more crucial during the induction of LTP into the synapses (Passafaro et 
al., 2001; Shi et al., 2001). However recent evidences had shown it that 81 % of the 
synaptic pool of AMPA receptors is comprised of the GluA1/2 and only 15% by the 
GluA2/3 AMPA receptors (Lu et al., 2009). In the extra-synapse AMPA receptors are 
entirely GluA1/2 containing. 
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The presence of homomeric GluA1 receptors that are Ca2+ -permeable are debated 
widely (Lu et al., 2009; Wenthold et al., 1996). Some believe that Ca2+-permeable 
GluA1-homomeric AMPA receptors are inserted during LTP (He et al., 2009; Plant et 
al., 2006), others argue against the existence and essentiality of homomeric GluA1 
receptors for LTP (Adesnik and Nicoll, 2007; Bagal et al., 2005). Recent publications 
have indicated that Ca2+-permeable AMPA receptors might be needed to increase the 
synaptic strength of AMPA receptors without altering the number of AMPA recep-
tors, especially during drug related memory consolidation (Argilli et al., 2008; 
Bellone and Lüscher, 2006; Conrad et al., 2008). Thus subunit compositions and their 
spatio-temporal relevance of AMPA receptors, is still being researched. 
1.2.2 NMDA receptors 
NMDA receptors are one of the principle glutamate receptors on the post synaptic 
side of the membrane and exists functionally as a tetrameric complex of GluN1 with 
GluN2A and GluN2B mainly (Andersen et al., 2000; Wenzel et al., 1997). GluN1 is 
the mandatory subunit in this tetramer as it provides the binding site for the co-agonist 
glycine or D-serine (Wenthold et al., 2003) and can pair up with either GluN2A or 
GluN2B, which contain the binding site for glutamate. In hippocampus during early 
stages of development GluN2B is almost solely expressed but during synaptic matura-
tion the levels of GluN2A goes up. This change in abundance in subunits is called the 
GluN2B to GluN2A developmental switch (Liu et al., 2004). The GluN2 subunit also 
governs the channel kinetics of these receptors and the presence of GluN2B causes 
the channel to have 3-4 times slower decay time (Monyer et al., 1994). 
NMDA receptors are co-incidence detectors. At resting potential the channel pore is 
blocked by Mg2+. Only when the pre-synaptic neuron releases neuro-transmitter and 
this can sufficiently depolarize the post-synaptic neuron beyond a threshold this Mg2+-
block is lifted and the channel can allow influx of ions. They are highly permeable to 
Ca2+ as well as Na+ and K+ ions. 
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1.2.3 Scaffolding proteins 
On the post-synaptic side of the synapse, just below the membrane, lies a class of 
scaffolding proteins, which are responsible for maintaining the complex protein archi-
tecture of the post-synaptic density. This group of proteins is called the DLG-
MAGUK family and it comprises of four members: chapsyn-110/PSD-93/dLg2, PSD-
95/SAP90/dLg4, SAP102/dLg3 and SAP97/dLg1. DLG-MAGUKs are known to 
share a common protein interaction motif. It comprises of three post-synaptic density-
95/Discs large/Zona Occuludens-1(PDZ) domains, Src homology 3 (SH3) domain and 
one enzymatically inactive guanylate kinase (GK) domain (Kim and Sheng, 
2004).The PDZ domains interact with the c-terminal end of many proteins like GluN2 
subunits (Niethammer et al., 1996) 
 
Figure 1: Domain organization of a DLG-MAGUK and its interacting partners, using PSD-93 as an exam-
ple. The PSD-MAGUK protein has three PDZ domains (shown in light brown), a SH3 (shown in blue) and a GK 
(shown in yellow) domain. The different N-terminal isoforms are generated by the alternative splice site (shown in 
white) of the protein. The different known interacting partners had been mentioned and the bar represents the 
specific domain (s) that they interact with. 
Despite their modular similarity and partially redundancy in certain functions, PSD-
MAGUKs have distinct N-terminal regions due to independent transcription start site, 
which set them functionally apart from each other. 
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1.2.3.1 PSD-95 and its synaptic properties 
PSD-95/dLg4 is the best characterized member of the dlg-MAGUK family. It has two 
N-terminal isoforms PSD-95 and PSD-95β. The N-terminal of  PSD-95  isoform is 
similar to the SAP97 isoform (Schlüter et al., 2006) and has a cysteine doublet that’s 
a substrate for palmitoylation (Topinka and Bredt, 1998). Palmitoylation is a special 
post-translational modification of conjugating a 16-C palmitic acid onto a cysteine 
residue by formation of a thio-ester bond. One interesting point about this modifica-
tion is that its labile and reversible and can happen faster than the half-life of a protein 
(Fukata and Fukata, 2010). Palmitoylation of PSD-95 targets it to the PSD and helps 
in the stabilization of AMPA receptors at the synapse (Craven et al., 1999). PSD-95 is 
also known to play a role in synaptic development as over-expression of PSD-95 
leads to faster maturation of excitatory synapse (El-husseini, 2014). 
In hippocampus, the principle isoform of PSD-95 is the  isoform. It interacts with 
AMPA receptors via the TARPs and helps in their synaptic trafficking and stability 
(Bats et al., 2007; Dakoji et al., 2003; Fukata and Fukata, 2010). 
Studies with genetic knockouts of PSD-95 have indicated that PSD-95 has no effect 
on AMPA and NMDA mediated basal synaptic transmission (Migaud et al., 1998) 
indicating a synaptic compensation for PSD-95 by other MAGUKs (Bonnet, 2011) 
but one report also claims that absence of PSD-95 in the knockout mice caused an 
increase in the number of AMPA silent synapses (Béïque et al., 2006). Over-
expression of PSD-95 however enhances AMPA receptor transmission (Elias et al., 
2006a; Nakagawa et al., 2004; Schlüter et al., 2006; Schnell et al., 2002). 
This ideas together advocate for the role of PSD-95 as a molecular slot protein for 
continues recycling of synaptic AMPA receptors (Schnell et al., 2002; Shi et al., 
2001). But studies on the PSD-95KO showed a contrasting increase in LTP whereas 
LTD was abolished (Béïque et al., 2006; Migaud et al., 1998). Combined this indi-
cates that PSD-95 is not directly required for AMPA receptor entry in synapse during 
LTP.  Rather PSD-95 might act a signaling scaffold to link NMDA receptor activation 
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with the downstream signaling cascade as well as act as a synaptic gate-keeper that 
limits the entry of AMPA receptors to synapses (Schlüter et al., 2006). Hence, in 
PSD-95KO animals AMPA receptors can access the synapse unhindered and thus 
cause an increase in the LTP.  
Though the NMDA receptor synaptic localization or functions in basal synaptic 
transmission are not compromised in PSD-95KO animals (Migaud et al., 1998), a 
higher percentage of GluN2B containing NMDA receptors are increased indicating 
the need for PSD-95 in the GluN2B to GluN2A developmental switch (Béïque et al., 
2006). Most group reports that neither over-expression, nor RNAi mediated knock-
down of PSD-95 had alters NMDA synaptic current levels (Béïque and Andrade, 
2003; Ehrlich and Malinow, 2004; Elias et al., 2006a; Nakagawa et al., 2004; Schlüter 
et al., 2006; Schnell et al., 2002; Stein et al., 2003), Futai et al (2007) claims to see 
increase in NMDA receptor EPSCs following PSD-95 over-expressions. 
1.2.3.2 PSD-93 and its synaptic properties 
Much about the role of PSD-93 is not very clear and is getting slowly unraveled. One 
reason for this being that PSD-93 is not as abundant as the rest of the DLG-MAGUKs 
and its functions are dependent on distinct brain region. PSD-93 knockout animals do 
not show any changes in synaptic transmission in cerebellum or motor behaviors 
(McGee et al., 2001a). In the cerebellum neurons, synaptic neurons could assemble 
and organize normally indicating that PSD-93 does not have any role in synaptic de-
velopment (McGee et al., 2001a). But when spinal dorsal horn neurons were cultured 
from PSD-93KO animals, the surface expression of GluN2 subunits of NMDA recep-
tors were reduced, but the level of AMPA receptors remained unchanged. The NMDA 
receptor currents were also reduced in the forebrain synapses in PSD-93KO animals 
and the NMDA receptor dependent persistent pain was also reduced (Tao et al., 
2003). Genetic knockout of PSD-93 doesn’t have any effect on the basal synaptic 
function in hippocampus but RNAi mediated knockdown showed a 50% reduction in 
AMPA currents (Elias et al., 2006a). Over expression of specific isoforms of PSD-93 
also showed to increase AMPA receptor mediated currents in hippocampus (Krüger et 
al., 2013a). 
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1.3 Apoptosis 
Programmed cell death or “apoptosis” was a term coined by Kerr et al (1972)  to dis-
tinguish a morphologically distinct form of cell death. Apoptosis had been known to 
occur normally during development and aging as a homeostatic mechanism to main-
tain the cell population. Apoptosis can be activated by a wide variety of stimuli, com-
ing both from outside or within the cell. Conditions both physiological and pathologi-
cal can trigger apoptosis but not all cells undergo apoptosis under similar stimulus, 
thus proving that there is a fine-control in the process of apoptosis. 
1.3.1 Mechanism 
The mechanism of apoptosis is highly complex involving an energy dependent cas-
cade of molecular events. There are two main pathways by which a cell might under-
go apoptosis: the extrinsic or the death receptor pathway and the intrinsic or the mito-
chondrial pathway. However, recent evidence had shown that both these pathways are 
linked and there are molecules from one pathway that can influence the other pathway 
as well (Igney and Krammer, 2002). Both the extrinsic and the intrinsic pathway con-
verge on the execution pathway, which is initiated by the cleavage of caspase-3 and 
results in DNA fragmentation, degradation of cytoskeletal and nuclear protein, mem-
brane disintegration and finally apoptotic body formation. 
The most significant group of enzymes that are required for the process of apoptosis is 
called caspases. They are a group of serine proteases that are expressed as inactive 
zymogens which when activated can activate other pro-caspases, thereby initiating a 
signaling cascade. Due to this sequential activation of one caspase by another caspase, 
the signal of apoptosis gets amplified and hence the resultant cell death process is 
rapid and irreversible. Caspases are classified as initiators (Caspase-2, -8, -9, -10), 
effectors or executioners (Caspase-3, -6, -7) and inflammatory (Caspase-1, -4, -5) 
(Cohen, 1997; Rai et al., 2005). 
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1.3.1.1 Extrinsic pathway 
The extrinsic signaling pathway that initiates apoptosis involves trans-membrane re-
ceptor mediated interaction. The sequence of events are best characterized with Fas 
L/Fas R and TNF-/TNF R1 models. When Fas ligand or TNF- binds to Fas recep-
tor or TNF Receptor 1 respectively, it results in the binding of adaptor proteins FADD 
or TRADD respectively (Grimm et al., 1996; Hsu et al., 1995; Wajant, 2002). FADD 
or TRADD associates with pro-caspase-8 via dimerization of a death effector domain 
and activates it auto-catalysis (Kischkel et al., 1995). Active caspase-8 can activate 
the effector caspase-3, which in turn completes the process of DNA fragmentation 
and subsequent cellular mortality. 
 
Figure 2: The extrinsic pathway of apoptosis. Members of the death receptor superfamily (FasL, TNF) causes 
activation of the extrinsic pathway of apoptosis. The binding of FasL to Fas induces receptor clustering and  for-
mation of the Death-Inducing Signaling Complex (DISC). This complex can recruit and activate caspase-8 from its 
inactive zymogen form. Active caspase-8 can activate the effector caspase (caspase-3, -6, -7) by direct cleavage 




Pro-caspase 8 Activated Caspase 8
Activated Caspase-3, -6, -7
Apoptosis
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1.3.1.2 Intrinsic pathway 
The intrinsic pathway of apoptosis involves a variety of non-receptor mediated stimuli 
that produce intra-cellular signaling events that act directly on the targets within the 
cell. These stimuli generate intra-cellular signals that cause change in the inner mito-
chondrial membrane resulting in an opening of the mitochondrial permeability transi-
tion (MPT) pore complex, loss of mitochondrial trans-membrane potential and release 
of two pro-apoptotic proteins, Cytochrome C and the serine protease, HtrA2, from the 
inter-membrane space into the cytoplasm (Saelens et al., 2004). These proteins bind to 
Apaf-1 and activates the procaspase-9 and forms an apoptosome (Chinnaiyan, 1999; 
Hill et al., 2004). This then activates the effector caspase-3 and leads the cell towards 
cell death. The over-activation of NMDARs and subsequent rapid influx of Ca2+ 
causes activation of two major pathways of apoptosis: 
1.3.1.2.1 MAP kinases pathway of apoptosis 
MAP kinases like P38 and JNK (c-Jun NH(2)-terminal kinase) when activated can 
activate the transcription factor p53 by phosphorylating it. When activated, p53 in-
duces the expression of pro-apoptotic proteins like Bax and Bad. These proteins can 
then go and induce permeabilization of the mitochondrial outer membrane causing 
release of cytochrome C and the subsequent steps of apoptosis that follows (Chipuk 
and Green, 2008; Liu et al., 2003).  
1.3.1.2.2 nNOS pathway of Apoptosis 
Excessive activation of NMDAR during excitotoxic challenges causes excess Ca2+ 
influx (Lipton and Rosenberg, 1994). The intracellular Ca2+ triggers the production of 
nitric oxide by activation of neuronal NO synthase (nNOS) in a Ca2+/Calmodulin 
(CaM)-dependent manner (Bredt et al., 1991; Garthwaite et al., 1988). Although, 
physiologic levels of NO is required for cellular functions, increased accumulation of 
intense nitrosative stress due to generation of reactive nitrogen species (RNS) can be 
detrimental to neurons. NO can have two modes of neurotoxic damage.  
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a) It can react to cysteine residues of target proteins to form s-nitrosothiols in a 
process called s-nitrosylation. S-nitrosylation of : 
i. Parkin (a ubiquitin E3 ligase) and PDI (protein disulphide isomerase, 
an endoplasmic reticulum chaperone) causes accumulation of mis-
folded toxic proteins (Chung et al., 2004; Lipton et al., 2005; Uehara et 
al., 2006; Yao et al., 2004). 
ii. Glyceraldehyde 3-P dehydrogenase (GAPDH) in the cytoplasm trans-
ducing in an apoptotic signal into the nucleus of neuronal cells (Hara et 
al., 2005). 
iii. Matrix metalloproteinase (MMP)-2/9, leading to a unique extra-
cellular pathway of excitotoxic cell death (Gu et al., 2002). 
b) In addition, it reacts with the reactive oxygen species (ROS) produced by mi-
tochondria, called superoxide anion (O2-) to form the extremely toxic peroxy-
nitrite radical (ONOO-) (Beckman et al., 1990; Lipton et al., 1993). 
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Thus, in general the intrinsic process of apoptosis in neurons can be summarized 
in Figure 3.  
 
Figure 3: Intrinsic pathways for neuronal apoptosis. Over activation of NMDARs and consequent influx of 
Ca2+ into neurons triggers activation of P38 MAPK, mitochondrial Ca2+ overload and release of cytochrome c 
(Cyt c), free radical generation (nitric oxide (NO+) and reactive oxygen species (ROS)), caspase activation and 
apoptosis. NMDARs are physically tethered to neuronal nitric oxide synthase (nNOS), facilitating its activation. 
The Bcl-2 family members Bad, Bax and Bid promote apoptosis mediated by glutamate, ROS and TNF-�, respec-
tively. Bcl-2 prevents apoptosis, apparently by attenuating cytochrome c release and ROS production. Activation 
of the p38 MAPK pathway by a Ca2+-mediated mechanism and possibly by oxidative stress may lead to phos-
phorylation/activation of transcription factors involved in apoptosis (Kaul et al., 2001).  
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1.4 NMDA Receptors: balancing neuro-protection and neuro-
toxicity 
NMDA receptors are known to play a very critical role in synaptic plasticity (Barria 
and Malinow, 2002; Carroll et al., 1999), synaptic development (Constantine-paton et 
al., 1990; Kerchner and Nicoll, 2008) and glutamate induced neurotoxicity (Choi, 
1988a; Tu et al., 2010a). Studies have found that NMDA receptor functions have been 
severely perturbed in a variety of CNS diseases ranging between traumatic brain inju-
ry, neuro-degeneration and ischemic stroke (Koutsilieri and Riederer, 2007; Liu et al., 
2007). Many suspect that glutamate induced neurotoxicity could be the underlying 
key-mechanism behind many of these CNS injuries. The mechanisms of glutamate 
induced neurotoxicity happens mostly through the NMDA receptors, owing to their 
high permeability to Ca2+, as opposed to AMPA receptors which are mostly Ca2+ im-
permeable (Tu et al., 2010a; Wenthold et al., 1996). The overly released glutamate 
from the presynaptic terminal during CNS injuries may cause excess Ca2+ loading via 
the NMDA receptors in the post-synaptic compartment and activate neuronal mortali-
ty genes (Benveniste et al., 1984; Okamoto et al., 2009). 
Pharmaceutical intervention approaches using NMDA receptor antagonists had been 
largely met with disappointing results at clinical trial levels (Kemp and McKernan, 
2002; Traynor et al., 2006). This is due to the fact that the different subunits of 
NMDA receptors, GluN2A and GluN2B, activate different intra-cellular signaling 
cascades upon activation. While the GluN2A activation has been shown to be pro-cell 
survival, the activation of GluN2B has been shown to be pro-apoptotic. Hence, a non-
specific blockade of NMDA receptor may block not only cell mortality but as well, 
the cell survival pathways in neurons. Thus targeting specific intra-cellular pathways 
downstream of GluN2A or GluN2B receptors may provide a better mechanistic con-
trol over the pathway we want to block during CNS injuries. 
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1.4.1 GluN2A receptors in neuro-protection 
NMDA receptors with the GluN2A subunit are known to have a protective function 
and responsible for cell survival during CNS injuries (Anastasio et al., 2009; Chen et 
al., 2008; DeRidder et al., 2006). NMDA receptor that contains the GluN2A subunits, 
are known to preferentially localize in the synaptic zone (Stocca and Vicini, 1998; 
Tovar and Westbrook, 1999). It is now predicted that location of a receptor, either 
synaptic or extra-synaptic, is a primary determinant of the down stream function that 
it has. In hippocampal neurons for example, the activation of GluN2A causes a pref-
erential activation of CREB, which in turn activates BDNF and cpg 15 gene expres-
sion and promotes cell survival (Chen et al., 2008; Hardingham et al., 2002). Again, 
Liu et al., 2007 found that in rat cortical neurons GluN2A activation from both synap-
tic as well as extra-synaptic pool, promotes cell survival and it does so by activation 
of the Akt-dependent pathway. 
In support of this existing hypothesis, experiments have shown that pharmacologic 
blocking of GluN2A leads increased cellular mortality during transient global ische-
mia in rats and causes potentiation of caspase-3 (Chen et al., 2008; DeRidder et al., 
2006). 
1.4.1.1 Signaling pathway 
The principle pathway, through which GluN2A imparts its neuro-protection during 
CNS injuries, is the GluN2A-PTEN-TDP-43 pathway (Zheng et al., 2012). GluN2A 
activation causes the reduction in expression level of PTEN (aka, Phosphatase and 
Tensin Homolog). PTEN is known to play a role in neuronal injuries such as ischemia 
and neurodegenerative diseases (Gary and Mattson, 2002; Omori et al., 2002). Sup-
pression of PTEN is known to increase cell survival (Cantley and Neel, 1999; Chang 
et al., 2007; Ning et al., 2004) by increasing the level of another nuclear pro-survival 
marker called TDP-43 (TAR DNA-binding protein-43). How TDP-43 helps cell sur-
vival is still vaguely understood. Nuclear knock down of TDP-43 is detrimental to 
neurons and promotes neuro degenerative signaling (Fiesel et al., 2010; Iguchi et al., 
2009; Zheng et al., 2012). So activation of GluN2A down-regulates PTEN, which in 
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turn up-regulates TDP-43 and increases neuronal cell survival. Interestingly GluN2B 
has no effect on PTEN expression. 
1.4.2 GluN2B in neuronal death and neuro-degeneration 
GluN2B in recent years had been credited mainly for the neuro-degenerative role that 
NMDA receptors play during CNS injuries. Recent findings claim that GluN2B acti-
vation is involved during neurotoxic insults (Liu et al., 2007; Tu et al., 2010a). How-
ever complete blockade of GluN2B receptors using pharmacologic antagonist haven’t 
been successful as they also interfere with the channels principle physiological func-
tions (Rodrigues et al., 2001; Walker and Davis, 2008; Zhao et al., 2005). 
1.4.2.1 Signaling pathway 
The activation of the apoptotic pathway via the Map Kinase P38 has long been asso-
ciated with glutamate excito-toxicity (Barone et al., 2001). Also, the role of NMDA 
receptor in activation of P38 has been proved (Kinases et al., 1999; Waxman and 
Lynch, 2005a). However the precise mechanism that regulates the duration and mag-
nitude of P38 activation is not completely understood. A key molecule that regulates 
the mechanism of P38 MAPK activation is the Striatal-enriched Tyrosine Phosphate 
or STEP, also known as PTPN5. This protein is known to be expressed specifically in 
the striatum, neo-cortex and hippocampus (Boulanger et al., 1995). Both STEP61 and 
STEP 46, the two isoforms of the protein (Bult et al., 1997) contain a highly conserved 
substrate-binding motif called the Kinase Interacting Motif (KIM) domain (Pulido et 
al., 1998). Phosphorylation of the Ser221 within this KIM domain renders the STEP 
enzyme inactive. This phosphorylation is mediated by a dopamine/D1 receptor medi-
ated activation of Protein Kinase A (aka, PKA) (Paul et al., 2000).  
Now when GluN2B subunit is activated for a brief time, it causes influx of Ca2+ ions. 
This causes de-phosphorylation of STEP by a Ca2+ dependent phosphatase calcineurin 
(Paul et al., 2003). Active STEP can contribute to neuronal survival by de-
phosphorylating and thus inactivating P38 MAPK. 
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But upon sustained GluN2B activation, another Ca2+-dependent protease called cal-
pain gets activated which can cleave STEP61 and can initiate a secondary activation of 
P38 (Xu et al., 2009). There are two kinds of calpain, the µ-calpain (calpain-1) which 
is more synaptic and the m-calpain (calpain-2), which is more extra-synaptic. In re-
cent years m-calpain activation  had been linked to a wide range of pathological status 
that includes stroke, neuro-degeneration and traumatic nerve injury (Liu et al., 2008; 
Vosler et al., 2008; Xu et al., 2009). It is believed that upon sustained activation of 
extra-synaptic GluN2B receptors, the m-calpain gets activated. This in turn cleaves 
the active STEP61 in its KIM domain, thus activating the extra-synaptically concen-
trated pool of P38.  
1.5 NMDA receptors, DLG-MAGUKs and Ischemia 
It was established so far that, NMDA receptors in addition to their roles in synaptic 
transmission have a very important role to play in ischemic brain injuries (Simon et 
al., 1984). But blocking the NMDA receptors have yielded no fruitful results, as it 
also blocked the synaptic transmissions of these receptors and caused detrimental ef-
fects in animals and humans (Aarts et al., 2002; Davis et al., 2000; Fix et al., 1993). 
Another alternative strategy was to block the down stream signaling pathways that 
connects NMDA receptors with the excito-toxic pathway without tampering with the 
synaptic transmission properties.  
PSD-95, the post-synaptic signaling scaffold molecule was known to couple NMDA 
receptors with intra-cellular signaling cascades (Brenman et al., 1996; Sheng, 2001). 
Using anti-sense PSD-95 oligo nucleotide in cortical neurons, that targets the PSD-95-
NMDAR interaction, neuronal mortality against NMDAR mediated neurotoxicity 
could be blocked (Sattler, 1999a). Since, suppression of PSD-95 is an impractical 
therapeutic strategy, owing to its very important role in maintaining post-synaptic 
transmission, a finer approach was adopted by targeting the PSD-95-GluN2B interac-
tion. This disruption was achieved by using an inhibitory peptide containing nine C-
terminal residues of GluN2B (KLSSIESDV; GluN2B9C) (Kornau et al., 1995a). This 
peptide was made cell permeable by fusing it with the cell-membrane transduction 
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domain of Human Immunodeficiency Virus-1 Tat protein (YGRKKRRQRRR; Tat) 
(Schwarze, 1999) to obtain the twenty amino acid peptide Tat-GluN2B9C. Admin-
istration of this peptide could decrease the neurotoxic vulnerability of cortical neurons 
to the same level as was observed in the PSD-95 knockdown cells. In addition it made 
neurons resistant to focal cerebral ischemia in vivo (Aarts et al., 2002). 
However the human genome has reported hundreds of different PDZ-domain contain-
ing proteins (Giallourakis et al., 2006) and each of the NR subunit C-terminal con-
tains a promiscuous PDZ interaction motif (T/SXV). Consequently the NR subunits 
might bind to other PDZ-domain containing proteins and mediate its neurotoxic prop-
erties independent of PSD-95. Alternatively, the Tat-GluN2B9C may also cause either 
its neuro-protection or additional side effects by perturbing the NR subunit-PDZ in-
teraction with a target other than PSD-95. 
1.6 Scope of the Thesis 
It is still unclear if PSD-93 has any essential role in maintaining surface level of glu-
tamate receptors and if this regulation is brain region specific. The first aim of the 
study was to identify if PSD-93 regulates the surface level of AMPA and NMDA re-
ceptors at excitatory synapse in mice visual cortex. There are various mechanisms by 
which receptor levels are maintained at neuronal membrane, including phosphoryla-
tion of specific residues on these receptors. I would like to check the mechanism by 
which PSD-93 might regulate the surface level of these receptors. Since NMDA re-
ceptors are also crucially linked with glutamate induced neurotoxicity during ischemic 
brain injuries, the second aim was to check the functional relevance that PSD-93 has 
in such forms of neurotoxicity and to identify which isoform(s) of PSD-93 is particu-
larly responsible for it. I also wanted to identify the molecular signaling pathway(s) 
that may be required by PSD-93 for linking glutamate receptor over-activation with 
apoptotic signaling during excitotoxicity. PSD-95 had been long identified as a link 
between NMDA receptor over-activation and neuronal apoptosis. I wanted to com-
pare, between PSD-95 and PSD-93, who has a more potent role in mediating the 
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NMDA receptor based neurotoxicity in cortical synapses and if they have the same or 
have different mode of operation during neurotoxic challenges. 
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2 Materials and Methods 
2.1 Molecular Biology 
2.1.1 Cloning 
Standard methods were followed for cloning (Sambrook, 2001). The chemicals and 
kits used for cloning were obtained from Bioline (Luckenwalde, Germany), Fermen-
tas/Thermofischer Scientific (Waltham, MA, USA), NEB (Frankfurt, Germany) and 
Qiagen (Hilden, Germany). 
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2.1.2 Polymerase Chain Reaction 
For amplification of specific DNA segments, the standard PCR method was employed 
(Saiki et al., 1985). The Table 1 below indicates the amount of the reagents used for 
the reactions: 
 
Table 1: PCR Reaction  
PCR Mix     
Template DNA 20 ng  
10x Reaction Buffer (Bioline/Fermentas) 2 µl  
dNTP’s (2.5 mM each, Bioline) 2 µl  
50 μM Forward primer 0.5 µl  
50 μM Reverse primer 0.5 µl  
Taq*/Pfu**Polymeras(Bioline/Fermentas) 1 µl  
  20µl   
PCR products were run on 1% agarose gel prepared in TAE buffer (0.2% 0.5 M 
EDTA, 1.14 ml/l Acetic acid, 30 mM Tris) to confirm and purify PCR products. 
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2.1.3 Restriction Digestion 
For confirming DNA constructs, and also preparing DNA fragments for cloning into 
vectors, restriction digestion was performed using restriction enzymes from Fermen-
tas and NEB in their respective buffer systems. The typical digestion reaction has 
been shown in table 
 
Table 2: Restriction Digestion Reaction 
Restriction Digestion Reaction Mix   
DNA sample 1 μl (1.5 μg)  
10X reaction buffer 5 μl  
BSA 0.5 μl  
Restriction Enzyme 2 μl  
H2O 41.5 μl  
  50 µl   
 
The reaction was incubated at 37°C, unless otherwise specified by the enzyme used, 
for 2 h. The digested sample was mixed with 1x TAE gel loading buffer and run on 
1% agarose gel. The band of the desired size was visualized and excised under a UV 
trans-illuminator. The excised product was further purified as mentioned in the next 
section. 
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2.1.4 PCR product and agarose gel purification 
The PCR product and restriction digested vectors were isolated according to the man-
ufacturer’s protocol from Qiagen (Hilden, Germany). The isolated fragments were 
eluted out in 30μl of 1:10 diluted elution buffer (Qiagen). The isolated fragments were 
used in subsequent steps of ligation. 
2.1.5 Ligation 
For the cloning protocol, inserts were ligated to different vector backbones in a molar 
ratio of 1:3. The vector was heated at 50°C for 5 min and snap chilled right before the 
reaction to avoid con-catamerization . The reaction was set as follows: 
 
Table 3: Ligation Reaction 
Ligation Reaction Mix     
Vector 1.5 ng  
Insert 0.5 ng 
 T4 DNA ligase buffer (Fermentas) 3 μl 
T4 DNA Ligase (Fermentas) 1 μl  
  30 µl   
The ligation was carried out at 16°C overnight. The ligation products were precipitat-
ed using 125 mM NaCl and twice volume of absolute ethanol. The precipitate was 
finally resuspended in 10μls of deionized water and 1 μl of this was used for trans-
formation. 
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2.1.6 Transformation 
1 μl of the ligation reaction was transformed into 50 μl of electro-competent XL1-
Blue Escherichia coli (E. coli) strain (Stratagene, Santa Clara, CA, USA) and colonies 
were cultivated on LB-agar plates containing ampicillin (100 μg/ml, Roth) 
 
2.1.7 Plasmid Preparation 
For amplification of the ligated plasmids, single colony was picked up from the trans-
formed bacterial plate and inoculated in either 5 ml (mini-prep) or 50 ml (midi-prep) 
of LB medium containing 100 μg/ml of ampicillin to select for only transformed cells. 
The cultures were allowed to grow overnight at 37°C under vigorous shaking. 
The bacteria was precipitated by centrifugation at 7000g for 10 min and the plasmid 
extraction was achieved following Qiagen (Hilden, Germany) DNA isolation protocol 
followed by alkaline lysis (Birnboim and Doly, 1979). To get rid of the RNAs, the 
samples were treated with RNase at 55°C for 5 min.  To purify the plasmid from all 
protein contamination, phenol-chloroform extraction was performed. To the plasmid 
extract, equal volumes of phenol:chloroform:isoamyl alcohol (25:24:1) (Applichem) 
was mixed and applied on a phase lock tube (Eppendorf).The clear aqueous phase 
isolated after centrifugation and mixed with an equal volume of chloroform and cen-
trifuged again. The aqueous phase was separated and the DNA was precipitated with 
0.7 volume of isopropanol and the pellet dissolved in 30 μl of elution buffer (Qiagen) 
for mini-prep and 300-400 μl for midi-prep. 
1 μl of the plasmid was run on 1% agarose gel in TAE buffer to confirm the concen-
tration. The sequencing of the constructs were performed and analyzed at AGCT Se-
quencing Facility of MPI-EM (Göttingen). 
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2.1.8 Genotyping 
PSD-93KO mouse line is described by McGee et al (2001b) and was kept in the insti-
tutes animal facility. For genotyping of the PSD-93 animals the protocol described by 
The Jackson Laboratory (Bar Harbor, ME, USA) was followed: 2 mm tail samples 
were used for the genotyping reactions at age P0 for knockout culture preparation and 
age P4-P6 for biochemical experiments with P20-P30 mice. Tail samples were mixed 
with 100-200 μl of PBND lysis buffer (10 mM Tris, 50 mM KCl, 2.5 mM 
MgCl2*6H2O, 0.1 mg/ml Gelatine, 0.45% (v/v) Nonident P40, 0.45% (v/v) Tween 
20, pH = 8,3) containing 1.2 mg/ml Proteinase K (Roth) at 55°C under 1000 rpm agi-
tation or  three hours under 1400 rpm agitation. Samples were then heated up to 99°C 
for 10 min in order to inactivate the proteinase K. The sample tubes were further cen-
trifuged on a tabletop centrifuge at highest speed for 5 min to separate the debris and 
2μl of the supernatant was used for subsequent PCR reactions (Table 5). The wild-
type allele showed a band corresponding to a molecular weight of 330 bp and the 
knockout allele showed a band of size 750 bp.  
 
Table 4: Primers used for wild-type and PSD-93 knockout animal genotyping. 
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Table 5: PCR mix used for wild-type and PSD-93 knockout animal genotyping 
 
PCR Mix     
Sample 2 μl  
10X TNK Buffer 2.2 μl  
dNTP’s (2.5mM, Bioline) 2 μl  
Primer 1 0.2 μl  
Primer 2 0.2 μl  
Primer 3 0.2 µl  
H2O 15 μl  
Mango Taq (polymerase) 0.2 μl  
  22 µl   
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Table 6: PCR program for wild-type and PSD-93 knockout animal genotyping. 
PCR Program       
 Time [min] Temperature [°C]  
Pre-incubation 2 94  
Denaturation 15’ 94  
Annealing 45’ 57 x35 
Elongation 1 72  
Final Elongation 4 72   
 
2.1.9 Constructs used during study 
For over-expression analysis of different N-terminal isoforms of PSD-93, bi-cistronic 
lentiviral constructs containing the N-terminus of different PSD-93 isoforms and the 
rest from rat PSD-93 sequence were used (named as FUp93xGW (x=α1/2, β, γ, δ, and 
ε) (Krüger et al., 2013a). For the knockdown of PSD-95, the lentiviral vector based 
constructs FRUGW, which contains RNAi against endogenous PSD-95 was used 
(Schlüter et al., 2006). 
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2.2 Cell Culture 
The chemicals used for performing cell culture was primarily ordered from Biochrom 
(Berlin, Germany), Sigma Aldrich (München, Germany), Millipore (Schwalbach, 
Germany), Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), Greiner Bio-
one (Frickenhausen, Germany), Invitrogen/Life Technologies (Darmstadt, Germany), 
Thermofischer Scientific (Waltham, MA, USA) and Roche (Mannheim, Germany). 
2.2.1 HEK293T cell line 
Human embryonic kidney, HEK293T was used for the preparation of small and large 
scale virus production. Cells were cultured in 10 cm cell culture dishes in presence of 
High glucose Dulbeccos’s Modified Eagle’s Medium (Biochrom) containing 10% 
fetal calf serum (Biochrom). Cells were incubated at 37°C for 2-3 days till they 
reached a confluency of 75-80% when they were passaged at a dilution of 1:15- 1:20.  
2.2.2 Lentivirus production 
Lentivirus particles for gene transfection were carried out in HEK293 cell line using 
HIV-1 packaging vector 8.9 and envelope glycoprotein vector Vsvg along with the 
plasmid of interest (Lewis et al., 1992). For small-scale production of virus particle 
from HEK293 cells, 6cm dishes and for large scale production, T-75 tissue culture 
flasks were used. The cultures were infected at 60-70% confluency with the amount 
of the various DNA constructs  given in the table below: 
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Table 7: DNA mix for lentivirus production. 
DNA construct Small Scale production Large Scale production 
Plasmid      2 μg      10 μg 
Δ8.9 vector      1.5 μg      7.5 μg 
Vsvg vector      0.5 μg      2.5 μg 
  
One day after the infection, the transfected plates were transferred to 32°C incubator 
with 5% equilibrated CO2 concentration in order to minimize cell mortality and in-
crease viral production. 
For small-scale virus production, the wells from 6 wells plates were harvested 2 days 
post transfection. The supernatant media was carefully collected and centrifuged at 
2000xg for 5 min to isolate the viral particles from the cell debris. The supernatant 
from this centrifugation, which contained the virus were isolated, aliquoted in 1.5 ml 
tubes and stored at -80°C freezer for further usage. 
For large-scale virus production, the supernatant of the T-75 flask was harvested and 
centrifuged at 2000xg for 5 min to separate the cell debris. This fraction is further 
passed through PVDF membrane with 0.45μm pore size (Millipore) and viral parti-
cles precipitated in an ultra-centrifuge at 36,500g for 1.5 h. The pellet containing the 
viral particles were left overnight to re-suspend in virus storage buffer (20 mM Tris-
HCl (pH = 8.0), 250 mM NaCl, 5% Sorbitol) and aliquoted and stored in -80°C for 
further usage. 
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2.2.3 Dissociated hippocampal culture 
Dissociated hippocampal cultures were prepared from P0 or P1 mice or rat hippo-
campi. The animals were anesthetized on ice for 2-4 min and then were decapitated. 
The brain was carefully taken out and placed in dissection solution (mGBSS) solu-
tion. The two hemispheres of the brain were separated using micro-dissection forceps. 
The meninges were carefully removed and an incision was made with a sharp micro-
scalpel on both ends of the hippocampus. Next, The hippocampus was folded out of 
the cortex and detached. The dentate gyrus was removed using a pair of forceps. The 
isolated hippocampi were transferred first to a fresh dissection solution and then to 
Enzymatic Solution (ES: 11.39 mM L-cysteine, 50 mM Na-EDTA pH=8, 10 ml DS, 
10 mM CaCl2, 1 N HCl, 100 μl 10 mg/ml DNase I, 100 μl Papain) and put on a mild 
rotation at 37°C for 30 min. After digestion the solution was replaced with Inactiva-
tion Solution  (IS: 10 ml 5% Serum Medium (25 ml Fetal Bovine Serum, 500 ml 
MEM without Earle’s salts and L-glutamine, 7.5 ml Hi-Glucose MEM, 1 ml Mito+ 
Serum Extender), 100 μl 10 mg/ml DNase I, 25 mg BSA) and the hippocampi were 
let to settle for about 2 min. The Inactivation Solution was next removed and replaced 
with one hub of 5% Serum media(25 ml Fetal Bovine Serum, 500 ml MEM without 
Earle’s salts and L-glutamine, 7.5 ml Hi-Glucose MEM, 1 ml Mito+ Serum Extend-
er). Using a 2ml fire-polished glass pipette, the hippocampi were triturated very gen-
tly couple of times and allowed to sit for another 2 min. The supernatant was collect-
ed in a fresh 10ml tube and the undigested chunks were resuspended again with one 
hub of 5% serum media and the procedure repeated. The supernatant was centrifuged 
at 500 g for 5 min and the supernatant was discarded. The pellet was resuspended in 
1ml of 5% serum media and cells were counted in a Neubauer chamber and 100.000 
cells were plated onto each well of Poly-D-lysine (PDL) pre- coated 24 well plate. 
The cultures were treated with FUDR (Sigma Aldrich) on DIV4 to restrict the further 
growth of astrocytes and were fed on DIV7 by exchanging half of the media with 
fresh media without Glutamate and Aspartate. Feeding was repeated every 3-5 days as 
was required. 
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2.2.4 Lentiviral infection of dissociated neuronal culture 
For transfection of dissociated culture, lenti virus carrying the plasmid of interest was 
used on DIV7. For each well of a 24 well plate about 100 μl of the small scale or 1 μl 
of the large-scale virus was used. Cultures were monitored for the fluorescence after 
DIV 12 and harvested between DIV 14-18 as was required for the experiment 
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2.3.1 Western Blotting sample preparation from dissociated neuronal culture 
For western blot analysis of dissociated neuronal cultures from mice or rat, primary 
cultures at DIV 14 or later, as per the requirement of the experiment, was washed with 
ice cold PBS with Mg and Ca. The cells were scraped out and harvested in 2x SDS 
sample buffer (3.3% Tris-HCl , 3.4% Tris, 8% SDS, 0.02% Sucrose, 0.03% EDTA, 
0.02% bromophenol blue, 0.27 % DTT (w/v)). For each well of a 24-well plate, 40 μl 
of 2X SDS Sample buffer and for each well of a 6 well plate, 200μls of the same was 
used. Samples were heated up to 55°C for 15 min with 1000 rpm agitation or at 95°C 
for 5 min without agitations. Samples were given a short centrifugation prior to stor-
ing them at -20°C until further usage. 
 
2.3.2 Co-Immunoprecipiation Assay 
In order to verify direct physical interaction between specific proteins in the cellular 
milieu, co-immunoprecipiation assays were performed. Primary mice cortical cultures 
in 6 well plates were washed in ice-cold PBS with Mg2+ /Ca2+. The cells were then 
harvested in RIPA lysis buffer (50 mM NaH2PO4, 150 mM NaCl, 1% Triton X-100, 
0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA and Roche protease inhibitor cock-
tail, pH = 7.4) and set on a rotator for 1h at 4°C. After 1 h, the lysate was centrifuged 
at 15,000xg for 30 min at 4°C. The clean supernatant was collected and was pre-
washed for 1hr at 4°C with protein A/G conjugated beads, that had already been 
washed and equilibrated in washing buffer (10 mM Tris/HCl, 1 mM EDTA, 250 mM 
NaCl, 0.5% TX-100, pH = 7.4), to avoid any non-specific interaction in the subse-
quent stages of the protocol. The supernatant was centrifuged at 7000 rpm for 15 min 
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at 4°C. To the supernatant was added 1μg of antibody to pull down the primary pro-
tein of interest. The binding was established by an over-night incubation at 4°C with 
mild rocking. The next day, a small aliquot of this tube was collected and kept on ice 
as the input sample for further processing. To the rest of the tube, protein conjugated 
beads were added and incubated for another 2 h at 4°C with mild rocking. The anti-
body and bead bound proteins were pulled down by applying a centrifugation of 7000 
rpm at 4°C for 15 min. The precipitate was washed in washing buffer for three times 
of 5 min each and lastly once with 1X TBS (pH7.4). Lastly, 2X SDS sample buffer 
was added to the bead bound proteins as well as the input sample and heated at 95°C 
for 10 min, centrifuged at 14,000xg for 1 minute and stored at -20°C until further use. 
 
2.3.3 Sub-cellular fractionation 
Isolation of crude synaptosomal and/or PSD fractions were done from mice or rat 
cortical cultures. Cells were washed from a 6 well plate with ice-cold PBS with 
Mg2+/Ca2+ and then scraped out in cold homogenization buffer (10 ml/one mouse cor-
tex, 320 mM sucrose, 10 mM HEPES/NaOH, pH 7.4) (Cho et al., 1992; Schlüter et 
al., 1999). The cell suspension was homogenized using 10-12 strokes in a Balch ho-
mogenizer with a pore size of 10 μ. The homogenate was next centrifuged at 1000xg 
at 4°C for 15 min. The supernatant (S1) was isolated and the pellet (P1) containing 
the cell debris discarded. The S1 supernatant was centrifuged at 10,000xg at 4°C for 
15 min to isolate the crude synaptosomal fraction (P2). The pellet was resuspended in 
the re-suspension buffer (50 mM NaF, 50 mM HEPES/NaOH, pH 7.4, 1 mM EDTA, 
0.2 mM NaVO4, 100 mM KCL, protease inhibitor cocktail (Roche)) for a final pro-
tein concentration of 1 μg/μl approximately. Resuspended samples were treated with 
1% Triton X-100 for 15 min on ice and centrifuged at 32,000xg for 1.5 h in an ultra-
centrifuge. The supernatant formed the Triton soluble fraction (1TS) and the pellet 
was the Triton Insoluble PSD enriched fraction (1TP). The 1TP pellet was resuspend-
ed in re-suspension buffer and protein concentrations of fractions measured using a 
BCA kit (Pierce). 2X SDS sample buffer was finally added and samples boiled at 
55°C for 15 min and stored at -20°C until further use. 
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2.3.4 Western Blotting 
For the biochemical analysis of proteins isolated either from animal tissues, primary 
neuronal cultures or HEK cells, were run on a denaturing  Bis-tris PAGE (Graham et 
al., 2005; Shapiro et al., 1967) followed by wet wetern blotting (Towbin et al., 1979) 
onto nitrocellulose or PVDF membranes. The gels for electrophoresis were prepared 
following the given recipe: 
Table 8: Recipies for Bis-Tris gels used for Western blotting. 
10 % Resolving Gel (375 mM Bis-Tris, pH = 6.2 - 6.4) 
H2O 7.3 ml 
AMBA 6.7 ml 
3.5X Bis-Tris Buffer 6.0 ml 
10% SDS 100 μl 
10% APS 120 μl 
TEMED 25 μl 
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3.5% Stacking Gel (375 mM Bis-Tris, pH = 6.2 - 6.4) 
H2O 6.2 ml 
AMBA 1 ml 
3.5X Bis-Tris Buffer 0.8 ml 
10% SDS 100 μl 
10% APS 96 μl 
TEMED 20 μl 
Approximately 10-30 μgs of proteins were run on the SDS-PAGE at 140V for 2 h or 
more until a good separation of the desired protein was achieved. The gel was next 
transferred onto a nitro-cellulose membrane in transfer buffer (25 mM Tris, 191 mM 
Glycin, 20% Methanol) at 250 mA for two hours at 4°C. The success of the preotein 
transfer was confirmed by staining the membrane with Ponceau S, a non-specific pro-
tein dye. The Ponceau S was washed off using TBS-T(20 mM Tris/HCl, 140 mM 
NaCl, 0.1% Tween20, pH = 7.6) and blocked with 5% BSA in TBS-T for 30 min at 
room temperature on a rocker. The membrane was washed with TBS-T for three 
times 10 min each. Primary antibody solutions were prepared in TBS-T containing 
2% BSA and 0.1% NaN3. Primary antibody incubations were performed for 2 h at 
room temperature or over-night at 4°C, with mild shaking. The membranes were 
washed for three times 10 min each with TBS-T and secondary antibody binding was 
performed in TBS-T for 2 h at room temperature in a light protected chamber. 
Afterwards, the membrane was washed with TBS-T three times 10 min each and a 
final wash in TBS (20 mM Tris/HCl, 140 mM NaCl, pH = 7.6) was performed for 5 
min at the very end. Visualization and analysis of band intensity was performed by 
using the Odyssey Infrared Imaging System (Li-COR Biosciences, Bad Homburg, 
Germany). Proteins were scanned using either the 700 nm or/and the 800nm channels, 
depending on the secondary antibody used. 
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2.3.5 Antibodies used for Immunoblotting 
For identification of proteins by western blotting, the following antibodies were used 
according to the indicated dilutions in table: 
Table 9: List of antibodies used for immunoblotting. 
Antibody Dilution Manufacturer 
Primary antibodies 
α-PSD-95 (mouse) 1:5000 Neuromab 
α-PSD-93 (mouse) 1:5000 Neuromab 
α-mortalin (mouse) 1:10000 Neuromab 
α-β-tubulin (rabbit) 1:7500 Licor 
α-GluN2A (rabbit) 1:5000 Epitomics 
α-GluN2B (mouse) 1:5000 Neuromab 
α-GluA1 (rabbit) 1:5000 Cell Signaling 
α-GluA2 (mouse) 1:5000 Neuromab 
α-phospho-GluN2B (Y1472) (rabbit) 1:2500 Cell Signaling 
α-phospho-P38 MAPK (Thr180/ Tyr182) 
(D3F9) (rabbit) 1:2000 Cell Signaling 
α-Cleaved casp-3 (Asp175) (5A1E) (rabbit) 1:2000 Cell Signaling 
α-Non-phospho-STEP (Ser221) (D74H3) 1:2000 Cell Signaling 
Secondary antibodies     
α-mouse Alexa Flour 680 (goat) 1:15000 Odyssey Licor 
α-rabbit Alexa Flour 800 (goat) 1:15000 Odyssey Licor 
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2.3.6 Chemical Cross-linking of Cell surface proteins 
For quantification of the levels of proteins expressed on cell surface, a chemical 
cross-linking approach was taken by using a membrane-impermeable, bifunctional 
cross-linker bis(sulfosuccinimidyl)suberate (BS3) (Boudreau et al., 2012). For this 
mouse acute visual cortex slices were prepared from P20-P30 C57/BL/6 wild-type or 
PSD93 knockout mice in ice-cold sucrose cutting buffer (87 mM NaCl, 2.5 mM KCl, 
0.5 mM CaCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, 25 mM D- Glucose, 75 mM 
Sucrose). 
The animals were anesthetized using isoflurane and decapitated to take the brain out 
in ice-cold sucrose cutting buffer. 400μm thick whole brain slices were prepared from 
both hemisphere is sucrose cutting buffer using the Leica VT 1200S slicing device 
(Leica, Solmes, Germany). The slices were taken on a whatman no. 1 filter paper 
(Whatman, cat. no. 1001-070)soaked in ice cold sucrose cutting buffer. A chilled 
metal syringe barrel was used to take tissue punches from the layer 2/3 of visual cor-
tex slices and taken into 1 ml of HEPES buffer solution (1.2 mM CaCl2, 20 mM 
HEPES, 147mM NaCl, 100 mM dextrose, pH 7.4) spiked with 40μl of 52 mM BS3 
stock solution, added just prior to adding the tissue. The tubes were incubated at 4°C 
for 30 min on a rotator. The cross-linking reaction was quenched by adding 100μl of 
1M glycine stock (1:10 dilution) and was incubated for another 10 min at 4°C on the 
rotator. The tube was centrifuged at 14,000g at 4°C for 2 min and the supernatant was 
quickly discarded and replaced with 200 μl of cold lysis buffer (10mM Tris-HCl, 
150mM NaCl, 10mM EDTA, 0.1% SDS, 0.5% Deoxycholate, 1% NP-40, 150mM 
NaF, 1mM Na3VO4, Complete Protease inhibitor (Roche)). Using a glass-glass tissue 
homogenizer, the punches were homogenized using 5-6 up and down strokes. The 
homogenized samples were further sonicated for 5 sec at a setting of 4 W, on ice, to 
avoid heating up of the samples. 2X SDS sample buffer was added to it and heated at 
55°C for 15 min and stored at -20°C until further use. 
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2.3.7 NMDA Neurotoxicity protocol 
To check the effect of NMDA induced neurotoxicity, I performed a NMDA challenge 
protocol on cortical cultures prepared from P0-P1 mice (Zhang et al., 2010). Cultures 
in 24-well culture plates were treated with 30μM NMDA in presence or absence of 
10μM APV (added 10 min prior to NMDA treatment) for 1 hour at room temperature 
in a humid, 5% equilibrated CO2 reaction chamber. To block any APMA mediated 
excite-toxicity, 10 μM NBQX was also added 10 min before the NMDA treatment 
was done. After 1 hour, first half of the media was changed with fresh feeding media, 
without any drugs, and this process was repeated once more to dilute out any residual 
drugs from the media. The plates were transferred back to 37°C incubator with 5% 
equilibrated CO2 concentration, for further 24 hours. Cells were washed with ice-cold 
PBS with Mg2+/Ca2+. Cells were harvested in 2X SDS sample buffer and heated upto 
95°C for 10 min. The tubes were centrifuged at high speed for 1 minute and stored at 
-20°C for further use. 
2.3.8 Propidium Iodide staining 
For staining cells that are undergoing apoptosis I performed Propidium iodide staining 
of dissociated neurons (Kruman et al., 1997). Dissociated neuronal cultures on pre-
coated cover-slips were washed gently with ice-cold PBS and fixed at room tempera-
ture for 10 min using fixation solution (4% PFA, 4%sucrose). After fixation, the cells 
were washed three times with cold PBS for 5 min each at room temperature. 1 µl of 
Propidium iodide (1 µg/l stock) was added to each well of a 24-well culture dish and 
incubated at room temperature for 10 min in dark. Cells were next washed for three 
times with cold PBS for 10 min each and mounted on glass slides with 80% glycerol. 
Images were acquired using a confocal laser-scanning microscope (514 nm excitation, 
Zeiss LSM 710) with a 40x oil-immersion objective. Images were acquired and pro-
cessed using the software. 
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2.3.9 Drugs Used in cell culture and acute visual cortex punches 
All the drugs used are stored as powder at 4°C or as re-suspended aliquots at 4°/-20°C 
according to supplier’s instruction. 
Table 10: Drugs used in cell culture and acute visual cortex punches 
Drug Name Concentration Effect Supplier 
NMDA 30μM NMDA receptor agonist 
Ascent Scientific/Abcam, 
Germany 
APV 10μM NMDA receptor blocker 
Ascent Scientific/Abcam, 
Germany 
PP2 10μM Src family Kinase blocker 
Sigma-Aldrich (München, 
Germany) 
NBQX 5 μM AMPA Receptor blocker 
Ascent Scientific/Abcam, 
Germany 
Ifenprodil 10 μM GluN2B Subunit blocker 
Ascent Scientific/Abcam, 
Germany 
ZnSO4 30 μM 
GluN2A Subunit 
blocker Roth, Germany 
BS3 52 mM Protein Cross-linker Applichem, Germany 
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3 Results 
The role of PSD-93 in maintaining the levels of glutamatergic receptors still remains 
controversial. Some publications have shown that knockdown of PSD-93 has no ef-
fect on basal synaptic transmission in hippocampus as there are other PSD-MAGUKs, 
which could compensate for the role of PSD-93 (Carlisle et al., 2008; Elias et al., 
2006a; McGee et al., 2001b). Other publications have shown that in hippocampus, 
even though genetic knockout of PSD-93 has no effect on synaptic currents, a RNAi 
mediated knockdown of PSD-93 can cause the same effect as acute absence of PSD-
95 for basal synaptic transmission, i.e., a 50% reduction of AMPA currents (Elias et 
al., 2006a). Previous studies from our lab had also shown that in hippocampus, specif-
ic PSD-93 isoform have differential role in maintaining synaptic AMPA receptor 
strength (Krüger et al., 2013a). Further more, there had been mixed opinion as to the 
necessity of PSD-93 in maintaining synaptic level of NMDA currents. No effect of 
PSD-93 had been found on hippocampal NMDA current (Tao and Johns, 2006) 
whereas, in cortex, PSD-93 was reported to influence synaptic NMDA currents (Tao 
and Johns, 2006). 
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3.1 Only the surface levels but not the total level of NMDA 
receptors are reduced in PSD-93 knockout visual cortex 
synapses 
While some reports claim that PSD-93KO causes no change in the basal synaptic cur-
rent (Elias et al., 2006a; McGee et al., 2001a) others say that PSD-93KO has reduced 
NMDA current (Tao and Johns, 2006). One more observation was that PSD-93 seem 
to have different functions in different brain region, for example, while in hippocam-
pal synapse PSD-93KO has no effect on basal synaptic transmission (McGee et al., 
2001a), in cortical synapse PSD-93 does seem to influence the synaptic NMDA cur-
rents (Tao and Johns, 2006). Thus to look for the brain area specific role of PSD-93, I 
took an alternate biochemical approach to quantify the surface level of AMPA and 
NMDA receptors in PSD-93KO mice visual cortex synapses. I used tissue punches 
from the L2/3 of visual cortex from wild-type or PSD-93KO mice in the age range of 
P20-P30. I performed a surface protein cross-linking protocol using BS3 to cross-link 
the cell surface proteins in these punches. Non-cross-linked samples were used to 
measure the total amount of a particular protein (protein expressed on the cell surface 
as well as internal to the cell). In the cross-linked sample lanes, we could observe a 
high molecular weight cross-linked protein aggregate, which was difficult to quantify 
(Figure 4A). So I we quantified the monomeric bands for each of the proteins. In the 
non-cross-linked lane, the monomeric band represented the total level of the protein, 
whereas in the cross-linked lane, it represented the internal level of the protein, which 
could not be cross-linked (Figure 4A). We quantified the level of surface expressed 
protein using the following formula: 
                                      
                         
                      
 
For checking the membrane impenetrability of the cross-linker, BS3, we used both 
PSD-95 (Figure 4B) as well as β-tubulin proteins (Figure 4C (bottom)), both of which 
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are intracellular proteins.  
 Three independent biological replicates were performed during this cross-linking 
experiment and were taken for the western blot analysis together to minimize the er-
rors occurring in all the down-stream steps. 20 µg of proteins were used for each 
western blot analysis and probed with -GluN2A, -GluN2B, -GluA1, -GluA2 
and - β-tubulin antibodies at their previously mentioned concentrations. For second-
ary antibody treatment, alexa -mouse 680 and -rabbit 800 antibodies were used for 
visualizing proteins in 700 and 800 channels of the odyssey Li-Cor scanner, respec-
tively. 
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Figure 4: PSD-93KO has reduced surface NMDA receptor levels. A- Representative western blot 
from a surface cross-linking experiment. First and third lane are total level of protein in a non-cross-
linked WT and PSD-93KO samples respectively; second and fourth lane are internal levels of protein 
in a cross-linked sample. Here, I used GluN2B, as an example. There is a high molecular weight fuzzy 
heteromeric band of cross-linked GluN2B (shown with red arrows), that was hard to quantify and a 
monomeric band of intra-cellular GluN2b (shown with blue arrow), which was quantified. B-PSD-95 
antibody (top) was used as an intracellular control to show the membrane impenetrability of the cross-
linking agent. C- GluN2B, D- GluN2A. β-tubulin shows no change in levels across the samples (bot-
tom). E,F- Quantification for the surface level of GluN2B and GluN2A, respectively. The intensity of 
the surface levels of either GluN2B or GluN2A was normalized to the average WT surface level band 
intensity for the respective proteins. E- The PSD-93KO (shown in blue) showed a reduction from the 
WT level (shown in pink), p<0.05, T-Test. F- Quantification of the surface level of GluN2A. The PSD-
93KO (shown in blue) showed a reduction from the WT level (showed in pink), p<0.05, T-test. 
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Both PSD-95 (Figure 4B) and β-tubulin (Figure 4C(bottom)) are intracellular proteins 
that are inaccessible for the cross-linker. Consequently, they showed no change in 
intensity between the total and the cross-linked lane. This reassures that BS3 can just 
cross-link proteins, which are expressed on the cell surface. 
The first and the third lane represent the total amount of GluN2B or GluN2A, whereas 
the second and fourth lane represent the internal, non-cross-linked level of GluN2B or 
GluN2A from the wild-type and the PSD-93KO samples, respectively (Figure 4C and 
Figure 4D (top)). 
I normalized the surface level of GluN2B in each sample to the average of the surface 
level of GluN2B in the WT samples. The GluN2B subunit of NMDA receptors 
showed a reduction in surface expression level (Wt. average = 100 ± 1.878, vs. PSD-
93KO average = 63.44 ± 1.100, p < 0.05, n = 3.)(Figure 4E) 
Similarly, the GluN2A subunit of NMDA receptors showed a reduction in the surface 
expression level (Wt. average=100 ± 3.36, vs. PSD-93KO average = 70.44 ± 2.06, 
p < 0.05, n = 3) (Figure 4F). ß-tubulin didn’t show any cross-linking and was equally 
distributed across all samples.  
Thus the surface levels of both GluN2A and GluN2B subunits were reduced in the 
PSD-93KO animals.  
Since the surface levels of NMDA receptor were reduced in PSD-93KO animals, we 
also wanted to check, whether the total level of NMDA receptors was reduced in 
PSD-93KO animals. For this we analyzed the level of GluN2A and GluN2B receptors 
from the non-cross-lanes (Figure 5A and B). 
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Figure 5: Total level of NMDA receptors remain unchanged in PSD-93KO animals. A,B- repre-
sentative western blot from a surface cross-linking experiment. First and third lane are total level of 
protein in a non-cross-linked WT and PSD-93KO samples respectively. A- GluN2A, B- GluN2B. β-
tubulin shows no change in levels across the samples(bottom). C- Quantification for the surface level 
of GluN2A. The PSD-93KO (shown in blue) showed no significant reduction from the WT(shown in 
pink),p>0.05, T-Test. D- Quantification for the surface level of GluN2B. The PSD-93KO (shown in 
blue) showed no significant reduction from the WT (showed in pink). 
We compared the total levels of GluN2A and GluN2B between the wild-type and 
PSD-93KO. Levels of both GluN2A and GluN2B remained unchanged in PSD-93KO 
animals (Average intensity of GluN2A: WT: 100 ± 5.17, PSD-93: 115.09 ± 10.29, 
(p = 0.282, n.s.), n = 3; GluN2B : WT: 100 ± 9.55, PSD-93 : 123.55 ± 3.54, (p = 
0.119, n.s.), n=3 )(Figure 5C and D). 
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3.2 Surface levels of AMPA receptors remain unchanged in 
PSD-93 knockout visual cortex synapses 
 
 
Figure 6: PSD-93KO showed no significant reduction in surface AMPA receptor levels. A,B- 
representative western blot from a surface cross-linking experiment. First and third lane are total level 
of protein in a non-cross-linked WT and PSD-93KO samples respectively; second and fourth lane are 
internal level of protein in a cross-linked sample. A- GluA1, B- GluA2. β-tubulin shows no change in 
levels across the samples (bottom). C- Quantification for the surface level of GluA1 and GluA2, re-
spectively. The intensity of the surface levels of either GluA1 or GluA2 was normalized to the average 
WT surface level band intensity for the respective proteins. C- Quantification for the surface level of 
GluA1. The PSD-93KO (shown in blue) showed no significant reduction from the WT (shown in 
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pink),(p=0.302, n.s) , T-Test. D- Quantification for the surface level of GluA2. The PSD-93KO (shown 
in blue) showed no reduction from the WT (showed in pink), (p=0.791, n.s, T-Test). 
The first and the third lane represent the total amount of, whereas the second and 
fourth lane represent the internal, non-cross-linked amount of GluA1 or GluA2 from 
the WT and the PSD-93KO samples, respectively (Figure 6A and Figure 6B (top)). β-
tubulin was used as an internal housekeeping protein (Figure 6 (bottom)). 
When AMPA receptor levels were analyzed, the GluA1 subunit of AMPA receptors 
showed no reduction in surface expression level (Wt. average = 100 ± 4.49, vs. 
PSD93KO average = 82.69 ± 9.90, p = 0.302 (n.s), n = 2, T-test) (Figure 6C). 
The GluA2 subunit of AMPA receptors also showed no significant change in surface 
expression level (Wt. average= 100 ± 9.16, vs. PSD93KO average= 93.36 ± 18.90, 
p=0.791 (n.s), n=2) ß-tubulin was used as an intracellular control for the cross-linking 
reactions and showed no cross-linking between different samples (Figure 6 A, B (bot-
tom)). 
3.3 PSD-93 physically interacts with NMDA receptors in vivo 
Dlg-MAGUKs have been known to interact with glutamate receptors either directly 
(Kornau et al., 1995b; Niethammer et al., 1996) or via TARP proteins (Bats et al., 
2007).Although PSD-93 had been reported to be essential in regulating AMPA recep-
tor stabilization in mature synapses in conjunction with PSD-95 in hippocampus 
(Elias et al., 2006b) other brain regions like in spinal dorsal horn and forebrain 
showed that PSD-93 has no effect on AMPA receptor currents (Tao et al., 2003). Ra-
ther in spinal dorsal horn and forebrain, PSD-93 has been shown to be more important 
for NMDA receptor surface expression and synaptic function (Tao et al., 2003). Also, 
since in my experiments only the NMDA receptor surface expression pattern changed 
Results P a g e | 47 
    
 
in the PSD-93 visual cortex, I wanted to check if in the visual cortex synapses PSD-
93 has direct physical interactions with NMDA receptors.  
In order to do that, we performed a co-IP experiment. We used wild-type P20-P30 
animals and dissected out punches from the layer 2/3 of the visual cortex. 1µg of 
α-PSD-93 antibody was as the primary antibody. A no antibody negative control was 
performed to rule out any non-specific interaction of the lysate proteins with the se-
pharose beads. Subsequent steps of co-immuno-precipitations were followed and fi-
nally using protein G-sepharose, the PSD-93 protein was pulled down. 10 µl of the 
input was analysed along side of 25 µl of the co-IP sample on the western blot. The 
membrane was probed with α-PSD-93, α-GluN2A and α-GluN2B antibodies.  
 
Figure 7: PSD-93 showed interaction with both GluN2A and GluN2B proteins in vivo. The representative 
western blot shows a strong band for PSD-93 in the lanes marked as ‘Input’. The lane marked as IP:PSD-93, 
shows the Co-IP reactions where -PSD-93 antibody was used for immune-precipitation. Both GluN2B and 
GluN2A bands are marked in the picture. Both GluN2B and GluN2A bands are present in input as well as the 
IP:PSD-93 lanes, showing their interaction with PSD-93. In the co-IP lanes bands for the heavy chain (50KD) and 
light chain (25KD) are also visible. The ‘No Antibody’ lane shows no visible band for PSD-93 or any other pro-
teins. 
PSD-93 protein was identified at its expected molecular weight in both the input and 
the co-IP lanes (Figure 7). The GluN2B band was detected in the 700 channel in the 
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input as well as the co-IP lane. The GluN2A band was detected in the 800 channel in 
the input as well as the co-IP lane. The no-antibody pull down didn’t show bands for 
PSD-93 or any of the other proteins. Additional bands corresponding to the heavy 
chain (IgGFc) and the light chains (IgGFab) of the α-PSD93 antibody, used for the 
immune-precipitation, was detected at 50 KD and 25KD molecular weights respec-
tively in the co-IP lane.  
This experiment showed that PSD-93 has direct physical interaction with both 
GluN2A and GluN2B subunits of NMDA receptors in the synapses of layer 2/3 of 
mice visual cortex. This is supported by studies using X-ray crystallography to also 
find out physical reaction of PSD-93 with NMDA subunits (Fiorentini et al., 2013). 
Thus, PSD-93 might promote stabilization of GluN2A and GluN2B on the cell sur-
face by physically interacting with them and in the PSD-93KO, due to lack of this 
interaction, there could be a reduced surface level of NMDA receptors.  
3.4 Surface level of phospho-GluN2B subunit is reduced in 
PSD-93 knockout synapses 
Previous reports have identified the Tyr1472 of GluN2B as one very important site to 
get phosphorylated (Chen and Roche, 2007). The phosphorylation of Tyr1472 pre-
vents AP2 to bind to GluN2B molecules (Lavezzari et al., 2003; Roche et al., 2001). 
AP2 is an adaptor protein that aids in clathrin-mediated endocytosis of membrane 
proteins. Effectively, if the Tyr1472 stays phosphorylated, it will be inaccessible for 
endocytosis and hence there will be better retention of GluN2B on the membrane. 
Since, the PSD-93 mutants showed a lower level of surface GluN2B, I checked 
whether the phosphorylation level of GluN2B is altered in this mutant. 
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Figure 8: PSD-93KO has reduced level phosphorylated GluN2B on the cell surface. A- representa-
tive western blot from a surface cross-linking experiment. First and third lane are total level of protein 
in a non-cross-linked WT and PSD-93KO samples respectively; second and fourth lane are internal 
level of protein in a cross-linked sample. Top-Phospho-GluN2B (Y1472), middle- GluN2B, bottom- β-
tubulin. β-tubulin shows no change in levels across the samples . B- Quantification for the ratio of total 
level of phospho-GluN2B. The PSD-93KO (shown in blue) showed no significant reduction from the 
WT(shown in pink), p=0.66 (n.s) n=4, T-Test. C- Quantification for the surface level of phospho-
GluN2B. The PSD-93KO (shown in blue) showed significant reduction from the WT (showed in pink), 
p<0.05, n=4, T-Test. 
I used P20-P30 wild-type or PSD-93 mutant animals and performed a chemical cross-
linking protocol with tissue punches from the layer 2/3 of the visual cortex as before. 
Samples were used by western blot using the standard technique. The membrane was 
probed with -GluN2B and -Phospho-GluN2B (Y1472) antibodies. ß-tubulin anti-
body was used as a intracellular control.  
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The level of the monomeric GluN2B (Y1472) (top), GluN2B (middle) and β-tubulin 
(bottom) protein bands in the WT vs. the PSD-93KO was seen (Figure 8A).  
I quantified the ratio of the total level of phospho-GluN2B (Y1472). This shows the 
population of the GluN2B that gets phosphorylated at its Tyr-1472 site. All band in-
tensities were normalized to the average band intensity of the wild-type lane and ex-
pressed as a percentage. The graph shows, that the total level of phospho-GluN2B 
(Y1472) remains unchanged between WT and the PSD-93KO animals (WT average 
level = 100 ± 19.30, vs. PSD93KO average ratio = 87.64± 18.76, p = 0.66, n = 4) 
(Figure 8B).  
I also quantified just the surface level of phospho-GluN2B (Y1472). This represented 
the percentage of phospho-GluN2B (Y1472), which was expressed on the cell surface 
alone. The graph showed reduction of this ratio in the PSD-93KO animals (WT aver-
age ratio= 100 ± 10.27, vs. PSD93KO average ratio= 34.80 ± 18.44, p>0.05, n=4). β-
tubulin level stays unaltered across all cross-linked or non-cross-linked samples 
(Figure 8C). 
These results help us conclude that PSD-93 is not directly involved in the phosphory-
lation of GluN2B at Y1472 and that in its absence the total level of GluN2B phos-
phorylation remains unaltered. But since the surface percentage of GluN2B (Y1472) 
is reduced in the PSD-93 mutants, it shows that in absence of PSD-93 the distribution 
of the phosphorylated GluN2B changes. PSD-93 either stabilizes the phosphorylated 
form of GluN2B on cell surface or it helps the retention of GluN2B on the membrane 
by recruiting a kinase that does a local phosphorylation event at its Tyr1472 residue.
3.5 The level of GluN2B receptor is reduced in PSD-93 cortical 
but not in hippocampal cultures 
NMDA receptors had long been associated with glutamate induced ischemic brain 
injuries (Simon et al., 1984). I also observed a reduction in the surface expression of 
NMDA receptors in the PSD-93KO visual cortex (Figure 4). To test if the NMDA 
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induced neurotoxicity is also reduced in these animals, I needed to switch to dissoci-
ated neuronal culture, for its ease of performing a NMDA challenge experiment. But 
first I needed to confirm whether, in the PSD-93KO dissociated cortical cultures, the 
surface levels of NMDA receptors are altered, especially since I was using the whole 
cortex to make the dissociated culture instead of just the visual cortex. Since there are 
apparent discrepancies in the role of PSD-93 between hippocampus and cortex, as 
discussed earlier, I also checked the level of NMDA receptors in hippocampal neu-
rons. For this experiment, I made cortical or hippocampal dissociated cultures from 
P0-P1 wild-type and PSD-93KO mice. 
 
Figure 9: PSD-93KO  has reduced surface NMDA receptor levels in cortical culture. A,B- repre-
sentative western blot from a surface cross-linking experiment. (Top) First and third lanes are total 
level of protein in a non-cross-linked WT and PSD-93KO samples respectively; second and fourth 
lanes corresponds to the internal level of protein in a cross-linked sample. A- GluN2A, B- GluN2B. 
Mortalin shows no change in levels across the samples (bottom). C- Quantification for the surface level 
of GluN2A. The PSD-93KO (shown in blue) showed a trend towards reduction from the WT level 
(shown in pink) but didn’t reach significance, p=0.193 (n.s), n=3, T-Test. D- Quantification of the 
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surface level of GluN2B. The PSD-93KO (shown in blue) showed reduction from the WT levels 
(showed in pink), p<0.05, n=3, T-test. 
Surface protein cross-linking was performed on DIV 14 cortical cultures, using BS3 
to a final concentration of 52 mM and for the control wells DMFO was added (vec-
tor). Experiments were performed on three independent batches of culture for each 
reaction condition and analyzed by western blotting as before. Blots were probed with 
-GluN2A, -GluN2B and mortalin antibodies at their afore mentioned concentra-
tions.  
The monomeric GluN2A band could be seen in the wild-type and PSD-93KO non-
cross-linked and cross-linked lanes respectively. The band in the non-cross-linked 
lane represents the total amount of GluN2A in the cells, while the one in the cross-
linked lane represents the internal level of GluN2A, which was not cross-linked 
(Figure 9A (top)). Mortalin, a member of the Hsp70 family of chaperones, was used 
as an intra-cellular protein control (bottom). 
Quantification was done by normalizing all GluN2A surface level values with the 
average of the WT surface level value of GluN2A (Figure 9C). The graph showed a 
strong trend of reduction in the level of GluN2A in the PSD-93Ko culture but didn’t 
reach significance (GluN2A average surface. level in WT: 100 ± 6.05, PSD-93KO: 
71.70 ± 15.11, n=3, (p = 0.193, n.s.), T-Test). Mortalin was equally distributed across 
samples. 
We see the monomeric GluN2B band in the WT and PSD-93KO non-cross-linked and 
cross-linked lanes respectively. The band in the non-cross-linked lane represents the 
total amount of GluN2B in the cells, while the one in the cross-linked lane represents 
the internal level of GluN2B, which was not cross-linked (Figure 9B).   
Quantification was done by normalizing all GluN2B surface level values to the aver-
age of the WT surface level value of GluN2B. The graph shows a significant reduc-
tion in the surface level of GluN2B in the PSD-93KO culture (GluN2B average sur-
face. levels in WT: 100 ± 8.68, PSD-93KO: 60.90 ± 6.97, n=3, p < 0.05, T-Test). 
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Mortalin, used as the intra-cellular control, didn’t show any significant change across 
samples (Figure 10D). 
I performed a surface protein cross-linking on the DIV 14 hippocampal cultures as 
well and samples from three independent batches of cultures were analyzed by west-
ern blot. 
 
Figure 10: PSD-93KO has no change in surface NMDA receptor levels in hippocampal culture. 
A,B- representative western blot from a surface cross-linking experiment. (Top) First and third lanes 
are total level of protein in a non-cross-linked WT and PSD-93KO samples respectively; second and 
fourth lanes corresponds to the internal level of protein in a cross-linked sample. A- GluN2A, B- 
GluN2B. Mortalin shows no change in levels across the samples (bottom). C- Quantification for the 
surface level of GluN2A. The PSD-93KO (shown in blue) showed no change from the WT surface 
level (shown in pink), p=0.27 (n.s), n=3, T-Test. D- Quantification of the surface level of GluN2B. The 
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PSD-93KO (shown in blue) showed no change from the WT surface levels (showed in pink), p=0.34, 
n=3, T-test. 
We see the monomeric GluN2A band in the wild-type and PSD-93KO non-cross-
linked and cross-linked lanes respectively. The band in the non-cross-linked lane rep-
resents the total amount of GluN2A in the cells, while the one in the cross-linked lane 
represents the internal level of GluN2A, which was not cross-linked (Figure 10A 
(top)). Mortalin, a member of the Hsp70 family of chaperones, was used as an intra-
cellular protein control (bottom). 
Quantification was done by normalizing all GluN2A surface level values with the 
average of the WT surface level value of GluN2A (Figure 10C). The graph showed no 
reduction in the level of GluN2A in the PSD-93Ko culture in comparison to the WT 
(GluN2A average surface. level in WT: 100 ± 5.80, PSD-93KO: 88.61 ± 6.71, n=3, 
(p = 0.270, n.s.), T-Test). Mortalin was equally distributed across samples. 
We see the monomeric GluN2B band in the WT and PSD-93KO non-cross-linked and 
cross-linked lanes respectively. The band in the non-cross-linked lane represents the 
total amount of GluN2B in the cells, while the one in the cross-linked lane represents 
the internal level of GluN2B, which was not cross-linked (Figure 10B).   
Quantification was done by normalizing all GluN2B surface level values to the aver-
age of the WT surface level value of GluN2B. The graph shows no change in the sur-
face level of GluN2B in the PSD-93KO culture (GluN2B average surface. levels in 
WT: 100 ± 4.85, PSD-93KO: 89.30 ± 8.404, n=3, p = 0.346, T-Test). Mortalin, used 
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3.6 Linking PSD-93, NMDA receptors and Apoptosis. 
3.6.1 NMDA receptors are required for maintaining a balance between Neuronal 
Cell survival and neuronal Apoptosis. 
NMDA receptors signaling had been proposed to be one major mechanism for the 
choice a cell has to make between survival against apoptosis (Choi, 1988b; Tu et al., 
2010b). Our results from previous experiments indicated a reduction of NMDA recep-
tor subunits in PSD-93KO animals as well as primary cultures. Thus, we were curious 
to know, if absence of PSD-93 has any effect on the survival of neurons upon neuro-
toxic insults. To check this idea we first established a NMDA neurotoxic protocol. 
Cleaved casp-3 is a class of cysteine protease known to be an effector molecule pro-
duced during the later stages of apoptosis (Cohen, 1997; Porter and Jänicke, 1999). 
Hence, production of cleaved casp-3 was used as a marker for apoptosis. 
3.6.1.1 Increased cleaved casp-3 indicated increased cell mortality 
Though our model takes the level of cleaved casp-3 as a measure of apoptosis, active 
caspases were reported in non-apoptotic cells, as well (Campbell and Holt, 2003; 
Gilman and Mattson, 2002; Kuo et al., 2006; Williams et al., 2006; Yuan, 2006). 
There had been also reports claiming that increased caspase-3 levels may actually 
promote LTD in neurons by cleaving GluA1 receptors in synapses, rather than trig-
gering a cell death pathway (Chan et al., 1999; Glazner et al., 2000; Schnell et al., 
2002). Though the protocol adopted in those studies (Li et al., 2010) for NMDA 
treatment to induce active caspase formation were distinctly different from ours 
(Zhang et al., 2010), we still wanted to be sure that the increased level of cleaved 
casp-3 actually measured cellular mortality and not just LTD in cortical cultures. 
For this experiment we used a staining protocol using propidium iodide (PI). PI is a 
DNA binding dye that intercalates and measures nuclear condensation and fragmenta-
tion using fluorescence. PI in general is impermeable to the cell membrane. But dur-
ing advanced stages of apoptosis, the cell membrane loses its integrity and becomes 
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permeable to PI, which then goes and binds to the already fragmented nuclear DNA, 
giving it a characteristic punctate pattern. 
 
Figure 11: PI staining of NMDA challenged cortical cultures shows cell death. A, B- Two repre-
sentative fields of view under 40X magnification of NMDA treated neuronal cultures. A- Cortical neurons treated 
with 30 µM NMDA and 10 µM NBQX (to block AMPA receptor responses). The pictures show apoptotic neurons 
with damaged cell membranes and bright punctate structures in the nucleus (marked with red arrows), which are 
fragmented pieces of chromosomal DNA. B- Cortical neurons treated with 30 µM NMDA, 10 µM APV and 10 
µM NBQX. The APV treatment could completely block the membrane damage and punctate nuclear structures 
caused by the NMDA treatment. 
We used DIV 17 wild-type cortical cultures and performed a NMDA challenge exper-
iment with 30 µM NMDA for 1 hour, either in presence or absence of 10 µM APV. 
10 µM NBQX was always used to keep the AMPA receptors blocked from being ac-
tivated. After 24 hours of incubation, we performed the PI staining protocol on the 
cultures. 
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Figure 11A showed two representative fields of view under 40 X magnification which 
revealed, that after 24 hours of NMDA challenge, the cortical neurons manifested 
clear signs of damaged cell membrane. The cells lost their typical shape and the nu-
cleus also showed characteristic punctate structures that represent condensed and 
fragmented chromosomal DNA (marked with red arrows).  
The two representative fields of view showed that by blocking NMDA receptor ac-
tivity using APV, we could block the apoptotic effects of the NMDA challenge exper-
iment. The cells looked healthy and there was little to no staining of the nuclear DNA 
(Figure 11B).  
The above experiment proved that our NMDA challenge experiment and the corre-
sponding elevated levels of cleaved casp-3, was directly co-related to increased neu-
ronal mortality. 
 
3.6.1.2 Dose response Curve for NMDA induced excito-toxicity on cortical culture 
To find the optimal dose of NMDA that was necessary to evoke a neurotoxic effect on 
wild-type DIV 17 cortical neuronal cultures, we used different concentrations of 
NMDA ranging from 0-100 µM. Cells were treated with 10 µM of NBQX to block all 
AMPA receptor responses.  
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Figure 12: Dose-response curve of NMDA treatment on cortical neurons. A- Representative western 
blot image for the level of cleaved casp-3 upon NMDA treatment (Top). Concentration of NMDA are varied from 
10 µM to 100 µM. Mortalin levels remain unchanged over different samples lanes (bottom). B- Quantification of 
the concentration of NMDA (in µM) vs. intensity of cleaved casp-3 produced(normalized to the 30 µM NMDA 
dose). The level of cleaved casp-3 produced slowly increases until it reaches saturation after 30 µM NMDA con-
centration. 
Primary antibodies against cleaved casp-3 and mortalin were used in their aforemen-
tioned concentrations.  
I saw a gradual increase in the level of cleaved caspase-3 with increasing NMDA 
concentration. All the cleaved casp-3 band values were normalized against the aver-
age intensity of the 30 µM NMDA treatment lane (Figure 12A). 
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I quantified the levels of cleaved casp-3 by normalizing it to the average band intensi-
ty in the 30µM NMDA treatment lane. The dose-response curve shows that the in-
crease in the level of cleaved casp-3 reached a plateau after 30µM of NMDA concen-
tration (Average normalized intensity for 10 µM NMDA: 16.43 ± 11.46, 20 µM: 
33.14 ± 13.64, 30 µM: 100 ± 7.24, 50 µM: 98.32 ± 7.03, 100 µM: 101.11 ± 11.12, 
n=3). Mortalin was used as a loading control, which didn’t vary across the samples 
(Figure 12B). 
Thus, a concentration of 30 µM NMDA is sufficient to induce maximal level of neu-
ro-toxicity to cortical neurons. For all further experiments for NMDA induced neuro-
toxicity, 30 µM was used as the standard NMDA dose, unless mentioned otherwise. 
3.6.1.3 Time-course for NMDA induced excito-toxicity on cortical culture 
To check the time course for an NMDA mediated neurotoxic challenge, we chose 
different time points of NMDA treatment to monitor it’s effect on the mortality of 
cortical neurons. We took wild-type DIV 17 cortical neuronal cultures and subjected 
them to 30 µM NMDA treatment. We chose time points of 0 min, 10 min, 20 min, 30 
min, 1 hour, 4 hours and 8 hours for NMDA treatment. 
Biological replicates from independent batches of neuronal cultures were performed 
and samples were stored until further processed with the western blotting. 
Primary antibodies against cleaved casp-3 and mortalin were used in their usual con-
centrations.  
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Figure 13: Time course for NMDA treatment on cortical neurons. A- The cleaved casp-3 band at increasing 
time of incubation of cortical neurons with 30 µM of NMDA between 0 min till 8 hours (top). Mortalin concentra-
tion remains unchanged over all time points (bottom). B- Quantification of time vs. concentration of cleaved casp-
3 (normalized against the 1 hour time point concentration). The level of cleaved casp-3 steadily increases till the 1 
hour time point but drops for the 4 hour and 8 hour time points. The distribution can be fit to a lognormal distribu-
tion curve. 
The -cleaved caspase-3 antibody, which is a marker for apoptosis, showed a gradual 
increase in its level till 1 hour of NMDA treatment. But upon NMDA treatment for 
extended time points of 4 hours or more, the level of cleaved casp-3 gradually de-
creased (Figure 13A (top)). The level of mortalin remained unchanged across the 
samples (Figure 13A (bottom)). 
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For quantification, the cleaved casp-3 band values were normalized against the aver-
age intensity of the 1hour NMDA treatment lane. The intensities of cleaved casp-3, 
saw a gradual increase till 1 hour of 30 µM NMDA treatment, after which it started to 
decline (Average normalized intensity for 30 µM NMDA treatment for 0 min: 2.71 ± 
1.18, 10 min: 16.30 ± 6.00, 20 min: 34.51 ± 9.00, 30 min: 63.85 ± 16.38, 1 hour: 100 
± 15.65, 4 hour: 19.83 ± 5.16 , 8 hour: 6.52 ± 4.07 , n=3). Though the level of cleaved 
casp-3 in 4 hours and 8 hours time point did look much reduced, but the cells on mi-
croscopic observation showed signs of apoptotic damage. Upon plotting the time vs. 
intensity curve, we saw that it followed a lognormal distribution. Mortalin was used 
as a loading control, which didn’t vary across the samples. 
The results showed that upon activation of NMDA receptors for up till 1 hour the 
mortality of cortical neurons increased. Keeping NMDA receptors activated for an 
extended period of time (4 hours or more) decreased the level of cleaved casp-3. But 
even at those time points, the cells suffered apoptotic damage. This could indicate, 
that the first phase of NMDA receptor activation may trigger caspase-3 mediated pro-
grammed cell death. But continued activation of the NMDA receptors might lead to 
activation of caspase-independent forms of apoptosis (Borner and Monney, 1999; 
Stoka et al., 2001). Thus, as 1 hour of 30 µM NMDA treatment was sufficient to 
cause the highest degree of cell death by the caspase dependent pathway, for all fur-
ther experiments of NMDA challenge, I chose 1 hour incubation of as standard time 
point, unless mentioned otherwise. 
3.6.2 PSD-93 deletion causes reduced neuronal mortality in cortical cells upon 
NMDA challenge 
It had been proposed that NMDA receptors are crucial in maintaining a balance be-
tween neuronal survival and apoptosis. While GluN2B receptor containing NMDA 
receptors had been attributed to be pro-apoptotic in nature (Hardingham et al., 2002; 
Vanhoutte and Bading, 2003), the GluN2A receptors are supposed to be pro-cell sur-
vival (Anastasio et al., 2009; DeRidder et al., 2006). Since in the PSD-93KO animals 
the surface levels of GluN2B receptors were reduced, I wanted to examine if this had 
an effect on the NMDA mediated neurotoxicity levels in PSD-93KO cultures. 
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For this experiment, I took wild-type and PSD-93 knockout cultures at DIV 17. We 
challenged the cells with 30 µM of NMDA for 1 hour in presence or in absence of 
10µM APV, which had been added 5 min prior to the NMDA treatment. Cells were 
harvested after 24 hours. The experiments were repeated with independent batches of 
cortical cultures and results were analyzed on western blotting for the levels of 
cleaved casp-3. 
 
Figure 14: PSD-93KO cultures have reduced mortality upon NMDA challenge. A-Representative 
western blot showing the cleaved casp-3 level in WT vs. PSD-95KD culture in presence or in absence of APV. 
The cleaved casp-3 protein (top)  could be blocked by APV treatment and the mortalin, stays equally distributed 
across all the samples (bottom). B- Quantification of the level of cleaved casp-3. The level of cleaved casp-3 in the 
wild-type (shown in deep pink) was reduced significantly in the PSD-93KO cultures (shown in light pink), p<0.05, 
T-Test. APV could block the effect of NMDA in both wild-type (shown in blue) as well as in PSD-93KO cultures 
(shown in light blue). 
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The band intensity for the cleaved casp-3 protein in the WT samples, treated with 
NMDA, was significantly reduced in the PSD-93KO treated with NMDA. The 
cleaved casp-3 levels could be almost entirely blocked in presence of APV in both the 
WT as well as PSD-93KO (Figure 14A (top)). The PSD-93KO culture also showed 
reduced signs of apoptotic damage when observed under microscope. Mortalin 
showed no significant difference across samples (Figure 14A (bottom)). 
To account for the difference in level of protein across different blots I normalized 
each band intensity to its corresponding WT NMDA treated band intensity and then 
expressed it as a percentage. So the wild-type NMDA treated sample has no variance 
as it is always 100 % and the other conditions are in relative to it. The PSD-93 cul-
tures showed a marked reduction in the level of cleaved caspase-3 (WT-NMDA : 100, 
Average of WT-NMDA+APV: 5.80 ± 1.95, PSD-93KO-NMDA: 28.10 ± 3.23, PSD-
93KO-NMDA+APV: 3.92 ± 0.61, p < 0.05, n = 3) (Figure 14B).  
Thus, this experiment proved that in absence of PSD-93 protein, there is a lower level 
of NMDA triggered neurotoxicity in cortical cells. This also followed the previous 
findings where the surface levels of NMDA receptors were reduced in PSD-93KO 
cortical neurons (Figure 9). Hence, lower surface levels of NMDA receptors in PSD-
93KO might lead to lower mortality upon activation of these receptors, as well. 
3.6.3 Over-expression of selected PSD-93 isoform can rescue the pro-apoptotic 
effect of PSD-93 
Since deletion of PSD-93 caused a significant reduction in the levels of cleaved casp-
3 and hence mortality of neuronal cultures were reduced, I wanted to examine, wheth-
er the over-expression of PSD-93 may rescue the neurotoxic phenotype in cortical 
culture. PSD-93 has six different isoforms. I over-expressed these PSD-93 isoforms 
against PSD-93 knockout culture background, to check if one or more of these 
isoforms are sufficient for rescuing wild-type levels of cleaved casp-3. 
For this experiment, I used P0 wild-type or PSD-93 knockout cortical cultures. On 
DIV 5, I transfected the PSD-93KO cultures with lentivirus constructs over-
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expression either of 1, 2, ß, γ, δ, ε isoform of PSD-93 (Krüger et al., 2013a). Each 
of these constructs, except the γ and the δ constructs, showed mild to dim level of 
fluorescence. The cells were harvested for western blotting on DIV 16 and expression 
of PSD-93 isoforms were analyzed by western blotting. 
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Figure 15: Over-expression of selected PSD-93 isoform rescues NMDA mediated neurotoxicity. 
A- Representative western blot showing the expression profile of different PSD-93 over-expression constructs 
(top). The first lane corresponds to the WT sample, second lane to the PSD-93KO sample, third till the eighth lane 
corresponds to the six different PSD-93 isoforms (α1, α2, β, γ, δ, ε) expressed against the PSD-93KO background 
respectively. Cleaved casp-3 shows no detectable signal (bottom). B- Representative western blot showing expres-
sion of cleaved casp-3 upon NMDA challenge in WT vs. PSD-93KO vs. PSD-93 isoforms over-expression system 
(top). Mortalin shows no significant change across different samples (bottom). C- Quantification of the level of 
cleaved casp-3 expressed upon NMDA challenge. Amount of cleaved casp-3 in WT samples (shown in pink) was 
reduced in PSD-93KO (shown in orange). Over-expression of PSD-91 (shown in navy blue), PSD-932 (shown 
in yellow) and PSD-93β (shown in green) could completely rescue the level of cleaved casp-3. Over expression of 
PSD-93δ (shown in brown) could only partially rescue the level of cleaved casp-3. Over-expression of PSD-93γ 
(shown in pale blue) and PSD-93ε (shown in pale brown) failed to rescue the cleaved casp-3 level completely.  
The cleaved caspase-3 levels could be blocked across all conditions when NMDA receptors were blocked by APV 
(shown in gray). 
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I checked for the expression profile of PSD-93. The wild-type lane showed a normal 
level of the different PSD-93 isoforms, as is expressed in a cortical cell. The PSD-93 
knockout lane showed an absence for the PSD-93 bands. The PSD-93 1 and PSD-93 
2 shows relatively lower expression levels but still it was comparable to wild-type 
levels of PSD-93. The PSD-93β, PSD-93 γ, PSD-93 δ and PSD-93 ε also showed a 
robust expression of the respective isoforms. The isoforms were identified by their 
slightly varying molecular weights (Figure 15A (top)). Mortalin was equally distrib-
uted over all the samples (bottom).  
I also checked for the levels of cleaved casp-3 in these cultures, to rule out any neu-
ronal mortality because of the lenti viral transfection protocol. Cleaved casp-3 gave 
no detectable signal, indicating, that there was no significant cell death caused by the 
transfection protocol (Figure 15A (bottom)). To ensure that the cleaved casp-3 anti-
body worked for this western, this blot was processed in parallel with the cleaved 
casp-3 blot when PSD-93 isoform over-expression rescued the cleaved casp-3 level 
(Figure 15B (top)). 
I performed the NMDA challenge experiment on DIV 17 on these cultures and ana-
lyzed the level of cleaved casp-3 by western blotting. 
I looked at the expression of cleaved casp-3 following the NMDA challenge experi-
ment. It could be seen that the level of cleaved casp-3 in the NMDA treated WT sam-
ple lane was significantly reduced in the PSD-93KO samples. The NMDA treated on 
PSD-93KO cultures over-expressing one of PSD-93 1, 2 and β isoform, was able 
to rescue the level of cleaved casp-3 to wild-type levels. The δ isoform could only 
partially rescue the levels. The PSD-93 γ and ε isoforms failed to rescue the level of 
cleaved casp-3 (Figure 15B (top)). Mortalin didn’t show any significant changes 
across the samples (Figure 15B (bottom)). 
I quantified the level cleaved casp-3 expression in this rescue experiment. Because of 
difference in level of protein across different blots, the intensities of each band was 
normalized against its corresponding WT samples treated with NMDA and then ex-
pressed as a percentage. The wild-type sample hence, has no variance as its always 
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100% and every other band are in relative percentage to it (WT-NMDA: 100 ± 0, Av-
erage WT-NMDA+APV: 5.80 ± 1.95, PSD-93KO-NMDA: 28.10 ± 3.23, PSD-93KO-
NMDA+APV: 3.92 ± 0.61, PSD-931-NMDA: 113.28 ± 14.08, PSD-931-
NMDA+APV: 24.71 ± 3.19, PSD-932-NMDA: 117.34 ± 5.02, PSD-932-
NMDA+APV: 4.06 ± 0.81, PSD-93β-NMDA: 100.79 ± 9.93, PSD-93β–
NMDA+APV: 9.40 ± 3.39, PSD-93γ–NMDA: 22.67 ± 7.85, PSD-93γ–NMDA+APV: 
13.70 ± 4.51, PSD-93δ–NMDA: 54.54 ± 17.98, PSD-93δ–NMDA+APV: 6.74 ± 3.76, 
PSD-93ε–NMDA: 33.29 ± 9.73, PSD-93ε–NMDA+APV: 6.46 ± 2.47, n=3) (Figure 
15C). 
This experiment showed that whereas down-regulation of PSD-93 causes reduced 
neurotoxicity in cortical cultures, over-expression of selected isoforms of PSD-93 
(1, 2, β) was capable of rescuing the neurotoxic phenotype. The PSD-93 δ isoform 
may be partially capable of rescuing and may need other isoforms for a full rescue. It 
also showed that the PSD-93γ and PSD-93ε failed to rescue the neurotoxicity com-
pletely. 
3.6.4 GluN2B is the major contributing NMDA receptor subunit for the NMDA 
mediated neurotoxicity 
Reports claim that GluN2A containing NMDA receptors tend to localize more in the 
synaptic zone (Stocca and Vicini, 1998; Tovar and Westbrook, 1999) and are pro-cell 
survival(Liu et al., 2007) whereas GluN2B containing NMDA receptors are more 
extra-synaptic and are pro-apoptotic in nature (Wang et al., 2013). Since PSD-93KO 
showed surface reduction in both GluN2A and GluN2B receptors but to varying de-
grees, I wanted to estimate the percentage contribution of these receptors in our 
NMDA challenge experiments. 
For this purpose, I wanted to block either the GluN2A or the GluN2B receptors using 
specific pharmacological antagonist and look for their respective contribution in 
NMDA mediated neurotoxicity. I used wild-type cortical cultures at DIV 17 and per-
formed our NMDA challenge experiments. I used 30 µM of Zn2+ for blocking 
GluN2A receptors, and 10 µM of Ifenprodil to block the GluN2B receptors. I used 10 
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mM APV to block all NMDA receptor subtypes. 10 µM NBQX was used in all reac-
tions to prevent any AMPA transmission. 
 
Figure 16: GluN2A vs. GluN2B contribution in NMDA mediated neurotoxicity. A- Representative 
western blot showing the level of cleaved casp-3 (top) in WT cultures treated with NMDA (30 µM) either in pres-
ence or absence of APV and Zn2+. Mortalin stays equally distributed in all samples (bottom).  B- Representative 
western blot showing the level of cleaved casp-3 (top) in WT cultures treated with NMDA (30 µM) either in pres-
ence or absence of APV and ifenprodil. Mortalin stays equally distributed in all samples (bottom). C- Quantifica-
tion of cleaved casp-3 normalized against the average WT NMDA treated band. There was small but significant 
change in the level of cleaved casp-3 from the WT NMDA treated (shown in pink) to the WT NMDA treated 
blocked with Zn2+ (shown in blue ), p<0.05, T-test. D- Quantification of cleaved casp-3 normalized against the 
average WT NMDA treated band. There was a significant change in the level of cleaved casp-3 from the WT 
NMDA treated (shown in pink) to the WT NMDA treated blocked with ifenprodil (shown in blue), p<0.05, n=3, 
T-test. APV treatment (shown in pale gray ) blocks the level of cleaved casp-3 in both C & D. 
Representative western blot image shows the effect of Zn2+ mediated blockade of 
GluN2A receptor on NMDA mediated neurotoxicity (Figure 16A). The first lane 
shows the level of cleaved casp-3 upon NMDA challenge when no NMDA receptor 
antagonists were used. The second lane shows that the level of cleaved casp-3 upon 
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NMDA treatment could almost completely be blocked upon using APV, which blocks 
all NMDA receptor subtypes. The third lane shows the amount of cleaved casp-3 
when Zn2+ blocks the GluN2A subunits.  
Upon quantification, I see that blocking the GluN2A subunit could reduce almost 25 
% of the effect of NMDA neurotoxicity. The level of mortalin, used as a loading con-
trol, didn’t change between samples. I normalized all band intensities to the average 
band intensity from the NMDA treated lane and expressed it as a percentage (Average 
intensity NMDA treated: 100 ± 2.38, NMDA + APV: 2.45 ± 0.26, NMDA + Zn2+: 
73.89 ± 2.31, n = 3, p < 0.05) (Figure 16C). 
Representative western blot image shows the effect of ifenprodil mediated blockade 
of GluN2A receptor on NMDA mediated neurotoxicity (Figure 16B). The first lane 
shows the level of cleaved casp-3 upon NMDA challenge when no NMDA receptor 
antagonists were used. The second lane shows that the level of cleaved casp-3 upon 
NMDA challenge could almost completely be blocked by APV. The third lane shows 
the amount of cleaved casp-3 when only the GluN2B subunits are blocked by ifen-
prodil.  
Blocking the GluN2B subunit by ifenprodil could reduce 80% effect of NMDA medi-
ated neurotoxicity. Mortalin remained unchanged across different lanes. I normalized 
all band intensities to the average band intensity from the NMDA treated lane and 
then expressed it as a percentage (Average intensity NMDA treated: 100 ± 5.16, 
NMDA + APV: 2.22 ± 0.83, NMDA + Ifen : 20.24 ± 0.81, n = 4, p < 0.05) (Figure 
16D). 
Thus, this experiments showed that the principle subunit, which is responsible for the 
NMDA mediated neurotoxicity was the GluN2B subunit as blocking it could prevent 
more than 80 % of NMDA neurotoxicity. It also fits to the current understanding of 
NMDA receptor mediated neurotoxicity where GluN2B receptors are thought to be 
more pro-apoptotic whereas GluN2A are more pro-cell survival (Wang et al., 2013, 
Liu et al., 2007). Zn2+ is a blocker for both GluN2A and GluN2B, but it is supposed to 
be specific for GluN2A over 30 µM concentration, below which it can also block 
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GluN2B. So, the 30 µM concentration of Zn2+, which I had used should be specific 
for GluN2A only. However, a partial blockade of a small percentage of GluN2B re-
ceptors cannot be ruled out. In that case, the effect of GluN2A on the process of 
NMDA neurotoxicity would be even lower. 
3.6.5 P38 MAPK activation profile during NMDA neurotoxicity challenge experi-
ment 
Several studies have shown that primarily the P38MAPK pathway is responsible for 
mediating the NMDA mediated neurotoxicity (Barone et al., 2001). So I wanted to 
check, if the neurotoxic activity of the GluN2B subunit was mediated by activation of 
P38.  
For this purpose, I checked for the activation profile of P38 MAPK in WT cortical 
neurons when challenged with NMDA. Since P38 MAPK is one of the early mole-
cules in the signaling cascade that activates the pro-apoptotic pathway in neurons, I 
chose time points of 10 min, 20 min, 30 min and 1 hour of treatment with NMDA and 
checked for the levels of active P38.  
To check if the level of P38 activation is transient or is maintained continually after 
NMDA challenge, I also measured the level of active P38, for each of the aforemen-
tioned time points, after 24h incubation. 
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Figure 17: P38 MAPK activation curve during NMDA challenge experiment. A- Representative 
western blot showing the level of active P38 MAPK in WT cultures treated with NMDA (30 µM) for different 
time points. B- Quantification of time vs. concentration of active P38 (normalized against the 1 hour time point 
concentration). The level of active P38 steadily increases from 10 min of NMDA treatment and reaches saturation 
after 30 min of NMDA treatment (black solid trend line) but comes down to control level post 24 incubation in 
fresh media (red solid trend line). The distribution can be fit to a exponential growth curve (black dotted line). 
 
The level of active P38 seems to increase from the control level following NMDA 
treatment right from 10 min of incubation. This increase in active P38 MAPK level 
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however drops close to base line when incubated in fresh media for 24 hours, post 
NMDA treatment (Figure 17A). 
I quantified the activation profile of P38MAPK upon NMDA challenge. For quantifi-
cation, all band intensities were normalized against the control untreated band average 
intensity and expressed as a percentage. The level of active P38 kept increasing but 
reached saturation after 30 min of NMDA treatment (Average normalized intensity 
for 30 µM NMDA treatment for control: 99.99 ± 31.05, 10 min: 362.7 ± 58.74, 20 
min: 364.32 ± 91.42, 30 min: 435.13 ± 171.69, 1 hour: 415.13 ± 115.68, n=3). After 
24 hours of incubation in fresh media however, the level of active P38 goes back to 
control level (Average normalized intensity for 30 µM NMDA treatment for control: 
99.99 ± 31.05, 10 min: 181.08 ± 70.83, 20 min: 143.78 ± 60.86, 30 min: 116.75 ± 
43.40, 1 hour: 118.91 ± 5.64, n=3). The dose-response data can be fit into an expo-
nential growth curve (Figure 17B).  
This showed that NMDA neurotoxicity via GluN2B does up-regulates the P38 MAPK 
which in turn may activate the downstream pro-apoptotic signaling cascade.  
3.6.6 PSD-93 show reduced levels of active P38 during NMDA challenge 
Our earlier results have shown a reduced surface GluN2B receptor in PSD-93KO neu-
rons. We also showed that PSD-93KO cultures also have reduced level of active 
caspase-3. Since we also confirmed in the previous experiment that NMDA challenge 
increases the level of active P38MAPK, we checked whether the level of active P38 is 
also reduced in PSD-93KO neurons. 
I performed 1 hour of 30 µM NMDA treatment on both WT and PSD-93 KO cultures 
in presence and in absence of APV and checked for the level of activated P38 imme-
diately after the NMDA treatment. Mortalin was used as a loading control. 
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Figure 18: PSD-93KO has reduced level of active P38 MAPK during NMDA challenge. A-(top) 
Representative western blot showing the active P38 level in wild-type vs. PSD-93KO culture in presence or in 
absence of APV (top). PSD-93KO could block rise in active P38 levels almost completely. APV also blocks the 
rise in active P38 in both WT as well as PSD-93KO cultures. Mortalin remains equally distributed across all sam-
ples (bottom). B- Quantification of the level of active P38 normalized against respective WT NMDA treated con-
trols. The WT active P38 level (shown in pink) was reduced in PSD-93KO cultures (shown in blue). APV could 
block this effect in both WT (shown in pale pink) as well as PSD-93KO cultures (shown in pale blue), p<0.05, T-
Test. 
The representative western blot image shows the level of active P38 in cultures treat-
ed with NMDA. The first and the second lane corresponds to WT and PSD-93KO 
cultures treated with NMDA and the third and fourth lane corresponds to WT and 
PSD-93 cultures treated with NMDA in presence of APV (Figure 18A). 
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For quantification of active P38 MAPK levels, I normalized all band intensities to 
their corresponding WT NMDA treated value. Thus, when expressed as a percentage, 
the wild-type showed no variance while all the rest showed levels relative to it. The 
PSD-93KO cultures showed a significant reduction in the level of active P38 upon 
NMDA challenge from its WT counterpart. Blocking the NMDA receptor activation 
by APV in both cases could prevent the activation of P38 (Average normalized P38 
intensity for WT NMDA: 100, PSD-93KO NMDA: 58.82 ± 6.81, WT NMDA+APV: 
41.72 ± 5.48, PSD-93KO NMDA+APV: 46.19 ± 9.84, n = 3, p<0.05, T-test) (Figure 
18B). 
3.6.7 PSD-93KO cultures have lower level of active P38 due of higher level of ac-
tive STEP   
A Striatal Enriched Protein Phosphatase or STEP is known to causes de-
phosphorylation of P38 MAPK, thus keeping it inactive in basal conditions. Previous 
studies had shown that during NMDA challenge, GluN2B mediated influx of Ca2+, 
causes activation of m-calpain, which is a Ca2+- dependent protease. Active m-calpain 
leads degradation of active STEP (Poddar et al., 2010). Degradation of STEP causes 
secondary activation in active P38 MAPK and hence promotes the downstream apop-
totic pathway. 
I checked whether in PSD-93KO animals the level of active STEP is altered. I per-
formed 1 hour of 30 µM NMDA treatment on both WT and PSD-93 KO cultures in 
presence and in absence of APV and checked for the level of non-phospho STEP (ac-
tive) immediately after the NMDA treatment.  
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Figure 19: PSD-93KO has elevated levels of active STEP during NMDA challenge. A- Representative western 
blot showing the active STEP level in wild-type vs. PSD-93KO culture in presence or in absence of APV. PSD-
93KO could block the reduction of active STEP. APV also blocks the reduction in active STEP in both WT as well 
as in PSD-93KO cultures. B- Quantification of the level of active STEP normalized against the average WT 
NMDA treated level. The WT NMDA treated sample (shown in pink) had reduced level of active STEP than in 
PSD-93KO cultures (shown in blue). APV treatment kept the level of active STEP to an elevated level in both WT 
as well as PSD-93KO cultures (shown in pale blue), p<0.05, T-test. 
Representative western blot showing the level of active STEP in cultures treated with 
NMDA (Figure 19A). The first and the third lane corresponds to WT and PSD-93KO 
cultures treated with NMDA and the second and fourth lane corresponds to WT and 
PSD-93 cultures treated with NMDA in presence of APV. 
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I quantified the level of active STEP between wild-type and PSD-93KO cultures on 
being treated with NMDA (Figure 19B). For quantification of active STEP, I normal-
ized all band intensities to the average WT NMDA treated lane and expressed it as 
percentage. Wild-type NMDA treated cultures showed reduction in the level of active 
STEP but PSD-93KO cultures showed a significantly elevated level of active STEP 
post NMDA treatment. Blocking the NMDA receptor activation by APV in both cases 
could keep the level of active STEP higher (Average normalized active STEP intensi-
ty for WT NMDA: 100 ± 0.42, WT NMDA+APV: 218.50 ± 12.83, PSD-93KO 
NMDA: 221.59 ± 18.03,  PSD-93KO NMDA+APV: 205.84 ± 21.02, n = 3, p<0.05, 
T-test). 
This experiment showed that following a NMDA challenge, when NMDA receptors 
are activated in WT neurons, it causes a reduction of the active STEP. This in turn 
helps to elevate the levels of active P38 MAPK, which can then trigger the apoptotic 
pathways in the cell. In PSD-93 due to reduced surface NMDA receptors (Figure 9), 
the active STEP remains higher even after NMDA exposure. This leads to lower level 
of active P38 MAPK and hence reduced level of apoptosis in these cells. 
3.7 Comparing the neuro-protection due to the loss of PSD-93 
and PSD-95 against NMDA mediated neurotoxicity in cor-
tical neurons 
3.7.1 PSD-95 deletion also causes a reduction in cortical culture mortality but to a 
lesser extent than PSD-93 deletion 
PSD-95 had been shown to be involved in interacting with c-terminal region of 
NMDA receptors via their PDZ 1/2 domain and promote their synaptic clustering by 
preventing GluN2B mediated internalization (Roche et al., 2001). Previous studies 
had been performed using anti-sense oligo-nucleotides against PSD-95 to show that 
absence of PSD-95 protected neurons against NMDA mediated excito-toxicity 
(Sattler, 1999a) and leads to enhanced cell survival in post-ischemic hippocampus.  
Neuronal NO had been thought to cause glutamate induced neurotoxicity in neurons 
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and it was found out that PSD-95 helps connect NMDAR mediated Ca2+-influx with 
NO production and hence promotes neurotoxicity (Sattler, 1999a). So I wanted to 
check whether deletion of PSD-95 has an effect on NMDA mediated neurotoxicity on 
cortical neurons. 
To achieve this, I used the lentiviral vector based constructs FRUGW, which contains 
RNAi against endogenous PSD-95 protein (Schlüter et al., 2006). Wild-type cultures 
were infected on DIV 7 with the lenti virus carrying the PSD-95 knockdown con-
struct. The transfection efficiency and infectivity were monitored using the GFP fluo-
rescence. Cultures were harvested on DIV 14 to check the knockdown efficiency of 
the FRUGW construct. 
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Figure 20: Knockdown of PSD-95 causes reduction in NMDA mediated neurotoxicity. A- Western 
blot showing efficiency of the FRUGW virus to knockdown PSD-95 in culture. The blot shows more than 95 % 
reduction in levels of PSD-95 (top). β-tubulin shows equal intensity in both lanes (bottom). B- Representative 
western blot showing the cleaved casp-3 level in wild-type vs. PSD-95KD culture in presence or in absence of 
APV (top). APV could block the cleaved casp-3 levels almost completely both in WT as well as PSD-95KD cul-
tures. Mortalin remains equally distributed across all samples (bottom). C- Quantification of the level of cleaved 
casp-3 normalized against the average of the WT NMDA treated sample. The WT cleaved casp-3 level (shown in 
pink) was reduced in PSD-95KD cultures (shown in light pink) (p<0.05, n.s., n=3, T-Test). APV could block this 
effect in both WT (shown in blue) as well as PSD-95KD cultures (shown in light blue).  
More than 95% of knockdown for the PSD-95 protein as compared to the wild-type 
uninfected control (Figure 20A (top)). β-tubulin was used as a protein loading control 
(Figure 20 (Bottom)). 
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I performed a NMDA challenge on both wild-type uninfected as well as the PSD-95 
knockdown cultures. After 24 hours incubation, the cells were harvested and quanti-
fied by western blot for the levels of cleaved caspase-3 protein. 
I could see a reduction in cleaved casp-3 levels in the PSD-95 knockdown cultures 
(Figure 20B). Mortalin levels remained unaffected across samples. 
The level of cleaved casp-3 in uninfected vs. PSD-95 KD cultures were quantified 
(Figure 20C). The band intensities in all lanes, from independent experiments, were 
all normalized to the average intensity of the uninfected WT NMDA treated culture 
and plotted as a percentage (WT-NMDA: 100 ± 5.04, WT-NMDA+APV: 2.75 ± 2.75, 
PSD-95KD-NMDA: 41.74 ± 6.88, PSD-95KD-NMDA+APV: 3.67 ± 0.91, p<0.05 
n=3). 
Thus, the down-regulation of PSD-95 can cause reduction in cleaved casp-3 levels in 
culture. Previous results indicate that PSD-93 was capable of reducing the level of 
cleaved casp-3 almost to the same or slightly higher degree. This may indicate that 
PSD-93, in spite of being a relatively low abundance MAGUK has a crucial role to 
play when it comes to NMDA mediated pro-apoptotic signaling. 
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3.7.2 Deletion of PSD-93 has a more severe effect on NMDA mediated neurotoxi-
city than deletion of PSD-95 
In the previous experiment I saw, that PSD-93 showed a greater reduction in cortical 
culture mortality than PSD-95, when challenged with 30 µM of NMDA. Next I want-
ed to see if at elevated doses of NMDA challenge, both PSD-93 and PSD-95 deletion 
could still be neuro-protective in nature. 
For this experiment, we used wild-type cortical cultures and PSD-93 knockout corti-
cal cultures. For knocking down PSD-95, I transfected on DIV 5, wild-type cortical 
cultures with the FRUGW construct. On DIV 17 of these cultures, I performed the 
NMDA challenge experiment on all three cultures. 
For the wild-type cultures I used a standard dose of 30 µM NMDA, as it had already 
been shown that 30 µM of NMDA is a saturating concentration for wild-type cortical 
neurons (Figure 12). For the PSD-93 knockout cultures and for the PSD-95 knock 
down cultures, I used doses of 30 µM, 50 µM and 100 µM NMDA. Cultures were 
harvested 24 hours after the protocol and analyzed by western blot for the levels of 
cleaved casp-3. 
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Figure 21: Deletion of PSD-93 provides better protection against NMDA induced neurotoxicity 
than deletion of PSD-95. A- Representative western blot showing the cleaved casp-3 level in wild-type vs. 
PSD-93KO vs. PSD-95KD culture in presence or in absence of APV (top). WT cultures treated with 30 µM 
NMDA. Both PSD-93KO cultures and PSD-95KD cultures were treated with three different NMDA concentra-
tions of 30 µM, 50 µM and 100 µM NMDA. APV could block the level of cleaved casp-3 completely in WT, 
PSD-93KO and PSD-95KD samples. Mortalin remains equally distributed across all samples (bottom). B- Quanti-
fication of the level of cleaved casp-3 normalized against the average of the WT NMDA treated sample. The WT 
cleaved casp-3 level (shown in blue dotted line) was measured as 100 percent. The PSD-93KO samples treated 
with 30 µM, 50 µM and 100 µM NMDA are shown by the black dots and joined by the black trend line. The level 
of cleaved casp-3 in the PSD-95KD samples treated with 30 µM, 50 µM and 100 µM NMDA are represented as 
red dots and joined with the red trend line. The PSD-93KO cultures showed reduced level of cleaved caspase-3 at 
all three concentrations of NMDA used. But in the PSD-95 knockdown cultures the level of cleaved caspase-3 
could be rescued back to wild-type level with increased dose of NMDA treatment.  
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The representative western blot shows that the 30µM dose of NMDA challenge cause 
a significantly reduced level of cleaved casp-3 in the PSD-93KO culture. Even with 
increasing concentration of NMDA, PSD-93KO failed to rescue the wild-type level of 
cleaved casp-3. In the PSD-95KD cultures, 30µM dose of NMDA showed a similar 
reduction in the level of cleaved casp-3, but with increasing concentration of NMDA, 
the level of cleaved casp-3 was rescued back to wild-type level. The production of 
cleaved casp-3 was almost completely blocked in presence of 10 µM APV. Mortalin, 
used as a loading control, stayed normal across all samples (Figure 21A). 
I quantified the cleaved casp-3 levels by normalizing each band of cleaved casp-3 
with their corresponding WT-NMDA band, to account for the differing amount of 
proteins between different blots. Even at 100 µM of NMDA PSD-93KO could only 
rescue up to 35 % of WT levels of cleaved casp-3, while at 100 µM of NMDA, PSD-
95KD could rescue the WT level of cleaved casp-3 completely. The band intensities 
of all reaction done in presence of APV was too weak to quantify and hence was not 
plotted. (Average intensity of WT-NMDA: 100 ± 0, PSD-93KO-30 µM 
NMDA: 19.46 ± 3.40, PSD-93KO-50 µM NMDA: 24.43 ± 1.95, PSD-93KO-100 µM 
NMDA: 34.79 ± 3.38, PSD-95KD-30 µM NMDA: 26.72 ± 3.56, PSD-95KD-50 µM 
NMDA: 71.95 ± 4.65, PSD-95KD-100 µM NMDA: 128.74 ± 3.42, n=3) (Figure 
21B). 
The above experiment indicated, that at lower doses of NMDA challenge, both PSD-
93 and PSD-95 are neuro-protective in nature. When the dose of neurotoxic NMDA is 
increased, PSD-95 knockdown can no longer do its neuro-protection, while PSD-
93knockout continues to be neuro-protective. This showed that in cortex PSD-93 has 
a more prominent role in NMDA mediated neuro-toxicity.  
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4 Discussion 
4.1 PSD-93 regulates surface levels of NMDA receptors in a brain region spe-
cific manner 
In recent years there has been much debate whether PSD-93 has a role to play in 
NMDA receptor function in synapses. Some reports suggest that even in absence of 
PSD-93 there is normal synapse assembly and maturation in cerebellum neurons 
(McGee et al., 2001a). But in spinal dorsal horn neurons, the surface expressions of 
NMDA receptors were reduced in PSD-93KO animals (Tao et al., 2003).When it 
came to effect of PSD-93 in the synaptic NMDA receptor function, the results were 
contradictory as well. While PSD-93KO animals had normal level of basal synaptic 
current in hippocampus, RNAi mediated knockdown of PSD-93 caused 50% reduc-
tion in AMPA receptor mediated current but not NMDA receptor mediated current 
(Elias et al., 2006a). On the contrary, Tao et al (2003) showed that in forebrain, PSD-
93KO caused a reduction in synaptic NMDA receptor current while the AMPA recep-
tor mediated current remained unchanged. While in younger animals (P20-30) There 
was no change in the AMPA/NMDA ratio in PSD-93KO animals, in older animals 
(P60-74), PSD-93KO were shown to have reduction, suggesting that PSD-93 also 
have a time-dependent change is functionality (Krüger et al., 2013b). All this reports 
point towards one direction that the role of PSD-93 is highly divergent and its func-
tion depends on specific brain region and developmental state of animals.  
Knowing this, I wanted to see how PSD-93 effects in the neo-cortex and chose the 
L2/3 of mice visual cortex for investigating the role of PSD-93. Since GluN2A and 
GluN2B are the two most important subunits of NMDA receptors in cortex, I checked 
for the levels of both of them. When I looked at the total levels of NMDA receptors, 
there seemed to be no change between WT and PSD-93KO animals (Figure 5). But the 
surface expression levels of NMDA receptors, both GluN2A and GluN2B subunits, 
showed a reduction in the PSD-93KO animals (Figure 4). However, no changes were 
found in the surface levels of AMPA receptors (Figure 6). The surface level of recep-
tors includes receptors located both in the synapse as well as extra-synapse and the 
protocol I used measured both this pool of NMDA receptors. It is possible to distin-
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guish between synaptic and extra-synaptic NMDA receptors by doing a sub-cellular 
fractionation protocol. Previous reports on cortical level of NMDA receptors had 
shown no variation in synaptic fraction of PSD-93KO mice (Bonnet et al., 2013). So 
this would indicate that changes in NMDA receptors that I see is more extra-synaptic 
in nature. 
To identify if PSD-93 and NMDA receptors have any in vivo physical interaction, I 
checked if PSD-93 co-immunoprecipitates with NMDA receptor subunits. Co-
immunoprecipitation protocol uses antibodies to precipitate one protein from a solu-
tion and checks if some other protein was co-precipitated with it. If this happens it 
means that the two proteins were either directly interacting with each other or they are 
part of a multi-protein interaction complex. Both GluN2A and GluN2B receptors was 
seen to co-immunoprecipitate when PSD-93 was pulled down (Figure 7). This 
showed that PSD-93 either directly interacts with NMDA receptors or it is physically 
bound to NMDA receptors via other interacting partner(s). A recent report using X-
ray crystallography and fluorescence polarization spectroscopic approach, to deter-
mine that PSD-93 indeed can interact with NMDA receptor c-terminal tail via its PDZ 
domain (Fiorentini et al., 2013) also supports my results.  
Considerable research has been done to find out the mechanism by which NMDA 
receptors are internalized. Studies have found a consensus sequence in the C-terminal 
tail of GluN2B subunits (-Y1472EKL-) that binds to the adaptor protein AP-2 (Roche 
et al., 2001). AP-2 is known to tag proteins having a YXXØ sorting signals (where 
X= any amino acid and Ø= bulky hydro-phobic amino acid) and mark it for clathrin 
mediated internalization (Review Traub, 2009). Thus, when AP-2 binds to the c-
terminal of GluN2B receptors, it gets internalized from the membrane. But when the 
Tyr-1472 in this internalization domain of GluN2B gets phosphorylated, AP-2 can no 
longer bind to it and hence, GluN2B cannot be internalized (Roche et al., 2001). 
Since in the PSD-93KO animals the surface of level of GluN2B was reduced, I want-
ed to check whether the phosphorylation status of the GluN2B-Y1472 is changed in 
these animals. I saw that the total level of GluN2B-Y1472 phosphorylation does not 
change in the PSD-93KO animals. This indicates that in absence of PSD-93, the sig-
naling pathway that phosphorylates GluN2B stays unperturbed. But when I checked 
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for the surface population of GluN2B, there was a reduction of the Y-1472 phosphor-
ylation in PSD-93KO animals.  
This could be because of two possible reasons. First, even if the level of phosphory-
lated GluN2B does not change, their cellular distribution changes in the PSD-93KO 
animals. This means that PSD-93 helps in the membrane stabilization of the phos-
phorylated form of GluN2B molecules. Second, this result could also indicate the Tyr 
1472 is not the only site that determines the surface stabilization of GluN2B recep-
tors, as is apparent from the fact that even with similar levels of GluN2B-Y1472 
phosphorylation, the sub-cellular distribution changed in PSD-93KO. Interestingly, 
there are other reported phosphorylation sites on GluN2B (Y1252, Y1336) which are 
reported to be important for their surface trafficking and stability (Nakazawa et al., 
2009; Takasu et al., 2002). The Src Family Kinase, Fyn, phosphorylates these sites 
(Nakazawa et al., 2009; Takasu et al., 2002). It will be highly relevant to check, if the 
level of phosphorylation on these sites are reduced in absence of PSD-93. This will 
further strengthen the idea of PSD-93 as a signaling scaffold, which acts as platform 
for post-translational modification of other PSD proteins. One other known fact is that 
the striatal enriched tyrosine phosphatase or STEP, is involved in the removal of Tyr 
phosphorylation of GluN2B (Salter and Kalia, 2004). I had already shown that in 
PSD-93 proteins there is higher level of STEP activity than wild-type when NMDA 
receptors are induced. It is possible that due higher level of STEP in PSD-93, there is 
lesser phosphorylation of one of the other Tyr sites of GluN2B and hence reduced 
membrane retention. 
As mentioned previously, different reports have different conclusion as to the necessi-
ty of PSD-93 in maintaining surface levels of NMDA receptors. One important con-
sideration in between these studies was that PSD-93 showed different roles in differ-
ent brain regions. So I tried to compare the role of PSD-93 in maintaining NMDA 
receptor surface levels between hippocampal and cortical dissociated culture models. 
The cortical cultures showed a reduction in the surface level of GluN2B (Figure 9). 
There was a trend in the reduction of GluN2A as well, but didn’t reach significance. 
The hippocampal cultures however showed no reduction in the surface levels of either 
GluN2A or GluN2B levels in PSD-93KO cultures. This again, supported the idea that 
PSD-93’s role is dispensable and redundant in the certain brain regions and some oth-
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er MAGUK may actually compensate for its loss of function (McGee et al., 2001a). 
But in cortex, PSD-93 is more crucial in maintaining the surface levels of NMDA 
receptors and its loss causes a reduction in the levels of NMDA receptors, particularly 
of the GluN2B subunit. 
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4.2 PSD-93 is required for NMDA induced neurotoxicity 
Glutamate induced neurotoxicity is one crucial reason for neuronal death during 
traumatic brain injuries (Choi, 1988a; Tu et al., 2010a). Owing to their high permea-
bility to Ca2+ ions, NMDA receptors, in particular, are suspected to be responsible in 
mediating this neurotoxic effect (Lu et al., 2009; Wenthold et al., 1996). Further stud-
ies have also indicated that during brain injuries, the release of excess amount of glu-
tamate from the pre-synaptic terminals causes activation of post-synaptic NMDA re-
ceptors. This may cause in a rapid influx of Ca2+ ions in the post-synaptic cell. Ca2+ is 
a well known second messenger system, which then activates pro-apoptotic genes in 
the cell and causes neuronal death (Sattler et al., 1998). Since, the PSD-93KO animals 
showed a reduction in the surface expression of NMDA receptors, I investigated the 
NMDA triggered neurotoxicity in these neurons. If the activation of NMDA receptors 
is required for neurotoxicity, then the reduction in the surface level of these receptors 
may reduce the level of neurotoxicity in PSD-93KO animals, as well. 
To test this hypothesis, I shifted my experimental model to dissociated neuronal cul-
tures. This was done because it’s relatively easy to perform a NMDA challenge ex-
periment in culture. While making the cortical culture, I used whole cortex from WT 
or PSD-93KO mice, instead of just the visual cortex. Since, changing my experi-
mental model from acute visual cortex punch to cortical dissociated culture was a 
major paradigm shift, I wanted to first check the levels of NMDA receptors in disso-
ciated culture system as well. The surface level of GluN2B subunit showed a reduc-
tion PSD-93KO cortical cultures (Figure 9B).  
Reports have claimed that GluN2B receptors are pro-apoptotic in nature (Liu et al., 
2007; Tu et al., 2010a). Which means GluN2B receptors, when activated, up-
regulates down-stream signaling cascades in the cell that leads to apoptosis (Kinases 
et al., 1999; Waxman and Lynch, 2005b). The level of the activated caspase-3, a ser-
ine protease needed for final stages of apoptosis, is classically used to measure the 
rate of apoptosis in cells (Zhang et al., 2010). When I performed a 30 µM NMDA 
challenge on WT cortical cultures for 1h and checked for the levels of activated 
caspase-3, no detectable signals were found. This could be because that activated 
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caspase-3 comes at a very late stage of apoptosis and hence just 1h of NMDA recep-
tor activation might not be enough time for the cell to activate caspase-3. So after the 
1h of NMDA challenge, I incubated the neuronal culture in fresh media for 24h and 
looked at the rate of apoptosis by measuring the levels of activated caspase-3. The 
neurons could show high intensity of cleaved casp-3 under western blot analysis.  
Interestingly some recent evidences had come into light, showing that caspase-3 is 
present in non-apoptotic cells as well Gilman and Mattson, 2002; Campbell and Holt, 
2003; Kuo et al., 2006; Williams et al., 2006; Yuan, 2006). So, to ensure that my 
NMDA challenge experiment indeed causes neuronal death, I used a PI staining pro-
tocol to mark apoptotic cells, post NMDA neurotoxic challenge experiment. 
PI staining in my wild-type cells treated with NMDA, showed clear morphological 
damages to the neuronal membrane. The nucleus of these cells showed characteristic 
punctate staining pattern, showing nuclear condensation and fragmentation (Figure 
11A). When cultures were pre-incubated with APV, which is an antagonist of the 
NMDA receptors, the apoptotic effects of NMDA could be blocked completely 
(Figure 11B). This showed that the increase in the level of caspase-3 in these cells 
corresponds to apoptotic cell death and is exclusively through the NMDA receptors 
activation. 
When the dose-response curve was plotted for a 1h treatment of varying concentra-
tions of NMDA, to check the level of apoptosis in WT cortical cultures, 30 µM was 
identified as a saturating concentration of NMDA for induction of apoptosis (Figure 
12). The time kinetics using 30 µM NMDA showed that the level of cleaved casp-3 
steadily increased until it reached a maximum at 1h (Figure 13). But when NMDA is 
kept on the culture for extended time-points of 4h or 8h, the level of cleaved casp-3 
showed a marked reduction. However, when the cells were studied under microscope, 
they still showed prominent signs of cell damage due to the NMDA treatment. This 
could have two explanations. One is that when NMDA receptors are activated for 4h 
or 8h, and then they are allowed to recover in fresh media for a further 24h, the level 
of apoptosis is much more advanced than 1h NMDA treatment would cause. At very 
advanced stages of apoptosis, there are multiple other proteases activated in a cell, 
which means even the activated caspase-3 might start getting degraded and their lev-
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els may go down. Hence even though these cells had reached advanced stages of 
apoptosis, the level of activated caspase-3, that could be quantified, is low. The sec-
ond explanation is that, during sustained activation of NMDA receptors, other caspase 
independent forms of apoptosis may gets activated and hence, even though the level 
of caspase-3 is low, non- caspase proteases may might compensate for it (Borner and 
Monney, 1999; Stoka et al., 2001). But for all further experiments, I used 30 µM of 
NMDA treatment for 1h as a standard for my neurotoxicity protocol, as it causes max-
imal activation of the caspase-3 dependent cell death pathway, unless mentioned oth-
erwise. 
When I performed the NMDA challenge on PSD-93KO cultures, they showed almost 
an 80% reduction in the level of cleaved casp-3 (Figure 14). The cells looked healthy 
under microscopic observation and showed negligible signs of apoptotic cell damage. 
Since PSD-93 has six N-terminal isoforms, I wanted to check which of them is in-
volved in mediating the NMDA receptor based neurotoxicity. For this reason, I over-
expressed these isoforms in a PSD-93KO background. When I checked for the ex-
pression level of these PSD-93 over-expression constructs, I found them to be compa-
rable to wild-type level of PSD-93 expression. This is particularly suitable for our 
study, as over-expressing a protein beyond physiological levels may often lead to un-
physiological effects. To make sure that the lentiviral mediated transfection protocol 
itself didn’t cause any neuro-toxicity, I also checked the level of cleaved casp-3 in all 
the over-expression cultures. None of them showed any detectable amounts of active 
caspase. When I performed the NMDA neurotoxicity protocol on these cultures, three 
of the N-terminal isoforms of PSD-93 (PSD-931, PSD-932 and PSD-93β) could 
rescue the levels of active casp-3 back to wild-type level. Two of the other isoforms 
(PSD-93γ and PSD-93ε) failed to rescue active casp-3 levels completely, while PSD-
93δ isoform could only partially rescue the neurotoxic effect of PSD-93. Not much is 
known about differential roles of N-terminal isoforms of PSD-93 in cortical synapses. 
The only study so far (Krüger et al., 2013b) had shown that in hippocampus, different 
PSD-93 isoform has differential expression levels and role in maintaining AMPA 
receptor functions. Thus, it could be likely that even in the cortex, they have differen-
tial role in maintaining NMDA receptor surface levels and hence functions differently 
in the rescue of neurotoxicity. 
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Since NMDA challenge can activate both GluN2A as well as GluN2B subunits of 
NMDA receptors, I wanted to see the contribution of either of these receptors in the 
NMDA mediated neurotoxicity in cortex. I used specific pharmacological antagonists 
to block either GluN2A (30 µM Zn2+) or GluN2B (10µM Ifenprodil) activation in 
wild-type neurons and then perform a NMDA challenge on them. When GluN2B re-
ceptor activation was blocked, there was almost a 80% reduction in NMDA mediated 
neurotoxicity (Figure 16B). This is almost in the same range of reduction in neurotox-
icity, as was observed in the PSD-93KO neurons. This also follows the current model 
of understanding that activation of GluN2B is neurotoxic in nature (Liu et al., 2007; 
Tu et al., 2010a). Blocking of the GluN2A molecule also showed about a small but 
significant reduction in neurotoxicity (Figure 16A). Generally GluN2A receptors are 
supposed to be neuro-protective in nature and their blockade had been attributed to 
increased neuronal mortality (Anastasio et al., 2009; Chen et al., 2008; DeRidder et 
al., 2006). So the reduction in neurotoxicity, when GluN2A receptors are blocked was 
unexpected. One explanation of this could be that, Zn2 that was used in this study to 
block GluN2A subunits is a promiscuous blocker of both GluN2A as well as GluN2B. 
Although the dose at which I used it, it’s supposed to block GluN2A receptors specif-
ically (Izumi et al., 2006), but a non-specific, partial blockade of GluN2B receptors 
could not be ruled out. In which case the reduction in neurotoxicity may be due to the 
partially blocked GluN2B receptors and not GluN2A receptors. I can verify the spe-
cific effect of GluN2A by RNAi mediated knockdown of the receptor. 
The P38 MAPK pathway has been known to be critical in the NMDA mediated neu-
rotoxicity (Barone et al., 2001). So I first I check if this pathway is getting activated in 
my model of NMDA mediated neurotoxicity. When looked at the time course of P38 
activation, I saw an increase in the level of active P38 immediately after 10 min of 
NMDA treatment, but reached saturation after 30 min of NMDA treatment (Figure 
17). The level of active P38 however came down to untreated control level post 24 h 
recovery time. The explanation of this lies in the fact that, P38 is one of the earliest 
proteins to be activated in the signaling cascade during NMDA induced form of apop-
tosis. Once active P38 has activated its downstream target proteins like p53, its level 
goes down and p53 can start activating the further steps of intrinsic apoptotic pathway 
(Chipuk and Green, 2008; Liu et al., 2003). Then I checked at the level of P38 activa-
tion in wild-type vs. PSD-93KO cultures after being treated with NMDA for 1h. 
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There was a reduction in the level of active p38 in the PSD-93KO cultures (Figure 
18). Reports have shown that the Striatal-enriched Tyrosine Phosphate or STEP, also 
known as PTPN5 down-regulates P38 MAPK activation in neo-cortex by de-
phosphorylating it (Boulanger et al., 1995). So I checked the level of active STEP in 
wild-type vs. PSD-93KO neurons. PSD-93KO showed higher levels of active STEP 
than in wild-type neurons. It is known that upon sustained activation of GluN2B sub-
unit, the influx of Ca2+ ions, at a very high concentration, can activate the Ca2+-
dependent protease m-calpain. Activated m-calpain can cleave active STEP and hence 
promotes secondary activation of P38 (Xu et al., 2009). Once activated, P38 can caus-
es phosphorylation of the pro-apoptotic transcription factor p53 which activates the 
intrinsic/mitochondrial pathway of apoptosis (Chipuk and Green, 2008; Liu et al., 
2003) (Figure 22). It is most likely that, in PSD-93KO animals due to lower level of 
surface GluN2B activation, there is much lower level of Ca2+-influx in the post-
synaptic cell during NMDA challenge. At such lower concentration of Ca2+, m-
calpain cannot be activated and hence it cannot cleave STEP to cause a secondary 
activation of P38. Since P38 remains inactive, it also cannot up-regulate p53 and thus 
the intrinsic pathway of apoptosis cannot be initiated (Figure 23). 
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Figure 22: NMDA mediated activation of intrinsic apoptotic pathway in wild-type neurons. A.In basal synap-
tic state, when NMDA receptors remain inactive, Striatal-enriched Tyrosine Phosphate or STEP (shown in grey) 
converts active phosphorylated P38 (shown in light grey) into inactive non-phosphorylated state. B. During 
NMDA mediated neurotoxicity, excess of glutamate released from the pre-synaptic terminal, following ischemic 
brain injury, leads to activation of NMDARs, especially ones with the GluN2B subunits and causes a rapid influx 
of Ca2+ (shown in orange) in the cell. At a very high concentration of intracellular Ca2+, a Ca2+-dependent protease 
m-calpain (shown in white) becomes activated that cleaves STEP and causes secondary activation of P38. Active 
P38 can phosphorylate the pro-apoptotic transcription factor p53 (shown in green), which in turn can initiate the 
intrinsic/mitochondrial pathway of apoptosis.   
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Figure 23: In PSD-93KO animals, NMDA mediated activation of apoptosis is blocked. A. In basal 
condition, PSD-93KO animals have less surface level of GluN2B containing NMDA receptors. STEP keeps P38 
protein in its inactive form by de-phosphorylating it. B. During NMDA mediated neurotoxicity, due to reduced 
level of surface NMDA receptors, low level of Ca2+ions can enter the post-synaptic cell. At such low level of 
intracellular Ca2+, the Ca2+-dependent protease m-calpain cannot get activated and hence STEP cannot be cleaved. 
STEP keeps the P38 in its inactive form and hence blocks all downstream signaling to initiate apoptosis. 
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4.3 Loss of PSD-93 is more neuro-protective than PSD-95 in 
cortical synapses 
Rapid Ca2+-influx that occurs through the NMDA receptors is the principal cause of 
neurotoxicity observed during ischemic brain injuries and this neurotoxicity cannot be 
reproduced by equivalent amount of Ca2+ loading via non-NMDARs and voltage-
sensitive Ca2+ channels (VSCC) (Sattler et al., 1998).This provides a crucial clue that 
Ca2+-influx through NMDARs are coupled to specific down-stream signaling path-
ways that can lead to neurotoxicity. Thus, it was proposed that the neurotoxic Ca2+-
signaling through NMDARs are linked to the down-stream signaling cascade by mol-
ecules with NMDARs interact (Sattler, 1999a).  
PSD-95 is known to interact with NMDA receptors and couple its activation to intra-
cellular signaling cascades (Brenman et al., 1996; Sheng, 2001). PSD-95 is known to 
interact with neuronal nitric oxide synthase (nNOS), an enzyme that helps nitric oxide 
formation in neurons (Dawson et al., 1991). The NMDAR-PSD-95-nNOS pathway 
was found to be the preferential pathway for NO production in neurons over other 
pathways (Craven and Bredt, 1998; Niethammer et al., 1998). Neuronal NO had long 
been postulated as a cause of glutamate induced neurotoxicity in neurons and it was 
found out that PSD-95 helps connect NMDAR mediated Ca2+-influx with NO produc-
tion and hence promotes neurotoxicity (Sattler, 1999b). This could be further validat-
ed by blocking NMDA mediated neurotoxicity by using anti-sense oligonucleotides 
against PSD-95 (Sattler, 1999b). 
As NMDAR-PSD-95-nNOS pathway started being viewed as the principal pathway 
for NMDA mediated neurotoxicity, this pathway became an intervention target for 
treating neuronal death caused by NMDA mediated ischemic brain damage. Pharma-
ceutical intervention by using NMDA receptor antagonists was met with failure as 
this leads to disruption of crucial physiological functions of NMDA receptors as well 
(Kemp and McKernan, 2002; Traynor et al., 2006). Suppression of PSD-95 was also 
an impractical therapeutic strategy, owing to its very important role as being a post-
synaptic scaffold molecule. Thus an alternate attempt was made in disrupting the 
NMDAR-PSD-95 interaction instead. This was done by using an inhibitory peptide 
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containing nine C-terminal residues of GluN2B (KLSSIESDV; GluN2B9C) (Kornau 
et al., 1995a) which was made cell permeable by fusing it with the cell-membrane 
transduction domain of Human Immunodeficiency Virus-1 Tat protein (YGRK-
KRRQRRR; Tat) (Schwarze, 1999) to obtain the twenty amino acid peptide Tat-
GluN2B9C. Administration of this peptide rendered neurons resistant to focal cerebral 
ischemia in vivo (Aarts et al., 2002). 
Few questions however remain open and unanswered. The C-terminal of GluN2 con-
tains a highly promiscuous PDZ interacting motif (T/SXV), which can interact with 
several PDZ domain-containing proteins, and any of them could mediate the neuro-
toxic signaling independent of PSD-95. Of all the several PDZ domain-containing 
proteins that physically interact with GluN2 receptors, both PSD-95 and PSD-93 are 
well known. The whole hypothesis that the neurotoxic Ca2+-signaling through 
NMDARs are linked to the down-stream signaling by MAGUK proteins, only consid-
ered PSD-95 and no one has paid much attention to the role of PSD-93 in the same 
process. Interestingly PSD-93 had been shown to co-localize with NMDA receptors 
and nNOS in cultured cortical neurons (Xu et al., 2004) and a very recent report also 
claims that there is lower nNOS mediated cell death in PSD-93KO cortical cultures 
(Zhang et al., 2010). Also while PSD-93KO animals had been shown to have reduced 
level of NMDA-dependent persistent pain (Tao et al., 2003). But surprisingly no one 
had ever looked at occlusion of stroke or NMDA-dependent persistent pain in PSD-
95KO animals, in spite of it being available for more than a decade (Migaud et al., 
1998). 
A pull down of GluN2 receptors followed by mass-spectrometric analysis of all the 
tightly bound protein that was co-immunoprecipitated with it had revealed both PSD-
95 and PSD-93 as two very strong interactor of GluN2 receptor (Husi et al., 2000).  
Most surprisingly, Cui et al (2007) had tried to check the binding affinity of Tat-
GluN2B9C peptide with several other PDZ domain containing proteins at an extreme-
ly low concentration of the peptide (0.007µM of Tat-GluN2B9C) to narrow down the 
subset of strongest interacting partners for this peptide. Both PSD-95 and PSD-93 
were seen to bind the peptide with equally strong affinity even at such low concentra-
tions. In the same study, PSD-95 showed a 16-fold higher affinity to bind to GluN2A 
containing NMDA receptors than GluN2B. Since GluN2A subunit of NMDA recep-
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tors are known to be neuro-protective in nature and helps cell survival during CNS 
injuries (Chen et al., 2008; DeRidder et al., 2006), one may wonder, why deletion of 
PSD-95, which has a much higher interaction with GluN2A, is neuro-protective in 
nature? One explanation to this seemingly tricky question could be in the fact that 
maturity of synapse had been shown to be important in making it susceptible to neu-
rotoxic challenge and immature synapses had been shown to be protected against glu-
tamate-induced toxicity (Choi and Kriegstein, 1987). I had also found it difficult to 
induce NMDA induced neurotoxicity in cultures that are younger than DIV 17. Over-
expression of PSD-95 is known to cause faster maturation of synapses (El-husseini, 
2014) whereas, I have already shown that in absence of PSD-95, synapses get arrested 
in an immature state (Bonnet et al., 2013). Whereas, this definitely is not a case for 
PSD-93 deletion as synapses have normal development even in it’s absence (McGee 
et al., 2001a)  Thus, the neuro-protective effect of PSD-95 deletion might be by keep-
ing the synapses in an immature state while that of PSD-93 might be through other 
molecular pathway(s). 
To check this I first examined the effect that PSD-95 knockdown had on NMDA me-
diated neurotoxic challenge. Deletion of PSD-95 was seen to be neuro-protective, 
though to a lesser extent than PSD-93KO cultures (Figure 20). This led me to compare 
the effect of neuro-protection that PSD-95 knockdown showed in comparison to PSD-
93 knockout when concentration of NMDA was increased. For the wild-type control 
culture, I chose 30µM dose of NMDA, as I already had demonstrated it to be a satu-
rating dose of NMDA for maximal activation of caspase-3. For the dose-response 
curve of NMDA concentration vs. activation of caspase-3 in PSD-93KO vs. PSD-95 
knockdown, I used 30 µM to 100µM concentration of NMDA. While the deletion of 
both PSD-93 and PSD-95 were neuro-protective in lower concentration, at higher 
concentrations of NMDA, PSD-95 knockdown cultures failed to be neuro-protective 
any more while, PSD-93KO cultures continued showing neuro-protection.  
So it is possible that while PSD-95 knockdown does its neuro-protection by arresting 
the synapse at an immature state and interrupting the NMDAR-PSD-95-nNOS path-
way. On the other hand, PSD-93 knockout might actually do its neuro-protection by 
interrupting both the nNOS and the P38 MAPK activation pathway and hence has 
increased neuro-protection. 
Discussion P a g e | 97 
    
 
4.4 Conclusion and outlook 
The current study helped us understand the role of PSD-93 in maintaining surface 
level of NMDA receptors in cortical synapses. We could demonstrate that PSD-93 
regulates the level of both GluN2A and GluN2B subunit of NMDA receptors while it 
plays no role in maintaining surface levels of AMPA receptors in the layer 2/3 of vis-
ual cortex synapses. Additionally, I showed that GluN2B receptor levels were regu-
lated in PSD-93KO animals independent of its Tyr1472 phosphorylation. The reduc-
tion of surface NMDA receptors could also be demonstrated in PSD-93KO cortical 
cultures, but in hippocampal cultures this reduction was not observed. 
I also demonstrated that PSD-93 is required for NMDA mediated neurotoxicity in 
cortex. It was shown that in absence PSD-93, the P38 MAPK pathway of apoptosis 
could not be triggered and hence neurons had increased neuro-protection during 
NMDA receptor mediated neurotoxic challenge. 
I could over-express the six different N-terminal isoforms of PSD-93 and identified 
three of them, which could completely (PSD-93α1, α2 and β) rescue the neurotoxici-
ty. As had been shown in hippocampus (Krüger et al., 2013b), possibly these are the 
most abundant isoforms of PSD-93 in cortex, as well. PSD-93δ could only do a partial 
rescue, which means it might need some other PSD-93 isoform or another MAGUK 
for its full functionality. The other two isoforms (PSD-93γ and ε) failed to rescue neu-
rotoxicity completely.  
Lastly, I could demonstrate that deletion of both PSD-95 and PSD-93 showed neuro-
protection at low concentrations of NMDA challenge. But at an increased concentra-
tion of NMDA challenge, PSD-95 deletion lost its neuro-protective ability, while 
PSD-93 deletion continued to show its neuro-protection. This demonstrated that in 
cortical synapses PSD-93 plays a more potent role than PSD-95 in coupling NMDA 
receptor activation and intra-cellular apoptotic signaling during NMDA neurotoxicity. 
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While our study gives us much knowledge and understanding about the roles of PSD-
93 in maintenance and physiological properties of NMDA receptors in cortex, there 
are still some very important aspects to be investigated: 
While we know that PSD-93 helps maintain the surface population of NMDA recep-
tors in visual cortex, we still need to identify whether the synaptic, extra-synaptic or 
entire pool of NMDA receptors is maintained by PSD-93. Some preliminary experi-
ments in our group (personal communication P. Favaro) had indicated that there is no 
change in the synaptic NMDA currents in visual cortex, which could mean that PSD-
93 maintains principally the extra-synaptic pool of NMDA receptors. I need to bio-
chemically isolate the synaptic and extra-synaptic fraction of NMDA receptors and 
determine which fraction has a reduced NMDA receptor in PSD-93KO animals. 
We need to check whether the neuro-protective role of PSD-93 in cultures is also val-
id in an in vivo mice-model of ischemic brain damage .I would also do a comparative 
analysis between PSD-93 and PSD-95 to see which one has better neuro-protective 
ability in vivo. 
Active caspase-3 had been shown to be present in cells even in non-apoptotic states 
known to be involved in cleaving AMPA receptor GluA1 subunit and promote LTD 
in synapses (Chan et al., 1999; Glazner et al., 2000; Schnell et al., 2002). LTD is not 
only important in regulating synaptic strength but important for causes spine shrink-
age and synaptic elimination called synaptic pruning (Bear et al., 1987; Cramer, 1995; 
M Constantine-Paton et al., 2003; Ziburkus et al., 2009). Since, PSD-93 has reduced 
ability to produce active caspase-3 when NMDA receptors are activated, it will be 
very interesting to check if LTD and synapse numbers are effected in PSD-93KO an-
imals and find out any co-relation with the basal level of active caspase-3 in these 
animals. 
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